{"gene":"BMX","run_date":"2026-06-09T22:02:45","timeline":{"discoveries":[{"year":1994,"finding":"BMX encodes a nonreceptor tyrosine kinase containing PH, SH3, SH2, and catalytic domains; immunoprecipitates of COS cells transfected with BMX and NIH3T3 cells expressing a BMX retrovirus contained a tyrosyl-phosphorylated BMX polypeptide, demonstrating intrinsic kinase activity.","method":"Transfection, immunoprecipitation, tyrosine phosphorylation assay","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct in-cell kinase activity demonstration with multiple cell systems in the original cloning paper","pmids":["7970727"],"is_preprint":false},{"year":1997,"finding":"BMX induces tyrosine phosphorylation and DNA-binding activity of STAT1, STAT3, and STAT5, and activates STAT1- and STAT5-dependent transcriptional reporter genes, independent of JAK kinase activation; this BMX-mediated STAT activation is specifically inhibited by PKCδ but not PKCβ1, PKCε, or PKCζ.","method":"Transient transfection in mammalian and insect cells, EMSA, reporter gene assay, co-expression with PKC isoforms","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (EMSA, reporter assay, phosphorylation), replicated across mammalian and insect cell systems","pmids":["9373245"],"is_preprint":false},{"year":1998,"finding":"BMX (Etk) is an effector of PI3-kinase: wortmannin blocked IL-6-induced Etk activation, constitutively active p110 activated Etk in absence of IL-6, and dominant-negative p85 blocked IL-6-induced activation; IL-6-induced neuroendocrine differentiation of LNCaP prostate cancer cells was abrogated by dominant-negative Etk.","method":"Pharmacological inhibition (wortmannin), dominant-negative/constitutively active PI3K subunit overexpression, cellular differentiation assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — three independent epistasis approaches (inhibitor, CA p110, DN p85) converging on same conclusion","pmids":["9520419"],"is_preprint":false},{"year":1998,"finding":"BMX and Tec activate serum response factor (SRF) in synergy with constitutively active Gα12/13, in a Rho-dependent manner (C3-sensitive); kinase and TH domains of BMX are required for SRF activation; kinase-deficient Bmx inhibits Gα12/13- and thrombin-induced SRF activation.","method":"Transient transfection, reporter gene assay, C3 toxin treatment, dominant-negative mutant expression","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple domain mutants, pharmacological blockade, and dominant-negative approaches in a single study","pmids":["9755164"],"is_preprint":false},{"year":1999,"finding":"BMX reconstituted PLCγ2-dependent signaling (calcium mobilization, ERK/MAPK activation, apoptosis) in Btk-deficient DT40 B cells, demonstrating a common Tec-kinase role as amplifier of PLCγ2-dependent signal transduction.","method":"Genetic reconstitution in Btk-deficient DT40 cells, calcium flux assay, ERK activation assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — genetic reconstitution in defined null background with multiple readouts","pmids":["10224128"],"is_preprint":false},{"year":1999,"finding":"Etk/BMX protects prostate cancer cells from apoptosis induced by PDT or thapsigargin; PI3K inhibitor LY294002 abolished Etk activity and increased apoptosis; dominant-negative Etk increased apoptosis, while Etk overexpression reduced it.","method":"Overexpression/dominant-negative Etk in LNCaP cells, pharmacological PI3K inhibition, PARP cleavage assay, DNA fragmentation","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss- and gain-of-function with pharmacological validation, single lab","pmids":["10362360"],"is_preprint":false},{"year":2000,"finding":"BMX is catalytically activated by IL-3 and G-CSF receptors in a PI3K-dependent manner; GFP-tagged Bmx translocated to cellular membranes upon co-expression of constitutively active PI3K; overexpression of wild-type Bmx in 32D cells induced apoptosis with G-CSF, while kinase-dead Bmx allowed granulocytic differentiation.","method":"Kinase activity assay, GFP-live cell imaging/membrane translocation, PI3K inhibitors, overexpression of WT vs. kinase-dead Bmx in myeloid progenitor cells","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Strong — membrane translocation directly observed, multiple complementary functional readouts, PI3K-dependence confirmed pharmacologically","pmids":["10962576"],"is_preprint":false},{"year":2001,"finding":"Etk/BMX directly associates with Pak1 via its N-terminal PH domain and phosphorylates Pak1 on tyrosine residues; this interaction was demonstrated by coimmunoprecipitation and GST-pulldown; Etk expression increased proliferation and anchorage-independent growth in breast cancer cells.","method":"Transient transfection, co-immunoprecipitation, GST-pulldown, in vitro kinase assay, anchorage-independent growth assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct binding (reciprocal Co-IP and pulldown) plus in vitro kinase assay showing phosphorylation of Pak1, single lab","pmids":["11382770"],"is_preprint":false},{"year":2001,"finding":"Etk/BMX is required for neuropeptide (bombesin/neurotensin)-induced androgen-independent growth of LNCaP prostate cancer cells; Etk activation requires FAK and Src but not PI3K; dominant-negative Etk blocks bombesin-induced growth and AR activation.","method":"Dominant-negative kinase overexpression, reporter gene assay (PSA promoter/ARE), AR transactivation assay","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — epistasis established using dominant negatives for FAK, Src, and Etk; single lab","pmids":["11713275"],"is_preprint":false},{"year":2001,"finding":"Native BMX associates with endogenous caveolin-1 in primary human umbilical vein endothelial cells; caveolin-1 expression reduces tyrosine phosphorylation of BMX/Btk family members; caveolin-1 scaffolding peptide suppresses the autokinase activity of purified recombinant Btk (functional model for BMX).","method":"Co-immunoprecipitation of endogenous proteins in HUVECs, transient transfection, in vitro kinase assay with caveolin-1 scaffolding peptide","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — endogenous Co-IP in HUVECs for Bmx-caveolin-1; single lab, autokinase suppression shown in vitro for Btk as functional model","pmids":["11751885"],"is_preprint":false},{"year":2001,"finding":"Bmx is expressed downstream of Tie-2 and VEGFR-1 in arterial endothelial cells; activated Tie-2 induced tyrosyl phosphorylation of Bmx protein and both Tie-2 and VEGFR-1 stimulated Bmx tyrosine kinase activity; Bmx knockout mice were viable without obvious phenotype, indicating a redundant role.","method":"Bmx knock-in/knockout mice (lacZ reporter), receptor activation assays, kinase activity assay","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo genetic model combined with direct kinase activity measurements downstream of defined receptors","pmids":["11416142"],"is_preprint":false},{"year":2001,"finding":"Etk/BMX is proteolytically cleaved by caspases during apoptosis, generating a C-terminal fragment (containing SH2 and kinase domains) with ~4-fold higher kinase activity than full-length Etk; ectopic expression of this fragment sensitized PC3 cells to apoptosis.","method":"In vitro translation with [35S]-methionine, incubation with recombinant caspases/apoptotic extracts, in vitro kinase assay, ectopic expression in PC3 cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with recombinant caspases, direct kinase activity measurement, functional validation in cells","pmids":["11278797"],"is_preprint":false},{"year":2002,"finding":"Etk/BMX forms a preexisting complex with TNFR2 in a ligand-independent manner through multiple Etk domains (PH, TH, SH2) and the C-terminal 16 amino acids of TNFR2; TNF activates Etk specifically through TNFR2 (not TNFR1); constitutively active Etk enhanced TNF-induced EC migration and tube formation while dominant-negative Etk blocked these.","method":"Co-immunoprecipitation, TNFR2-specific agonist, TNFR2-deficient cells, domain-deletion mutants, cell migration/tube formation assay","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — receptor-specific epistasis using KO cells plus Co-IP with domain mapping, multiple functional readouts","pmids":["12370298"],"is_preprint":false},{"year":2002,"finding":"Etk activation alone is sufficient to transcriptionally induce VEGF expression independent of HRE under normoxia; Etk utilizes both MEK/ERK and PI3K/Pak1 pathways to activate VEGF transcription; exogenous VEGF stimulates Etk tyrosine phosphorylation, forming a reciprocal Etk-VEGF autoregulatory loop.","method":"Northern/Western analysis, transient transfection with reporter genes, pharmacological pathway inhibition, antisense oligonucleotides","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal approaches in single lab, functional feedback loop demonstrated","pmids":["12483534"],"is_preprint":false},{"year":2003,"finding":"TNF induces reciprocal activation between Etk and VEGFR2 (transactivation complex); Etk phosphorylation at Tyr566 directly mediates recruitment of the p85 subunit of PI3K; TNF-induced EC migration requires VEGFR2-Etk-PI3K-Akt signaling, and is abolished in Etk-deficient ECs.","method":"Co-immunoprecipitation, VEGFR2-specific inhibitors, Etk-deficient ECs (genetic deletion), Akt/PI3K inhibitors, EC migration assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO ECs, specific phospho-site mutation, multiple inhibitors, and direct binding demonstrated","pmids":["14532277"],"is_preprint":false},{"year":2003,"finding":"Bmx interacts with p130Cas at membrane ruffles, phosphorylates Cas on tyrosine residues, and promotes Cas-Crk complex formation; a Bmx mutant failing to interact with Cas fails to induce cell migration; dominant-negative Cas blocks Bmx-induced membrane ruffling and cell migration.","method":"Co-immunoprecipitation, colocalization (membrane ruffles), tyrosine phosphorylation assay, haptotactic migration assay, dominant-negative Cas expression","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — binding, phosphorylation, and functional rescue/block shown with multiple mutants and orthogonal approaches","pmids":["12832404"],"is_preprint":false},{"year":2004,"finding":"Etk/BMX physically associates with p53 through its SH3 domain and the proline-rich domain of p53; DNA damage-induced p53 inhibits Etk activity; Etk-p53 interaction (primarily cytoplasmic) leads to bidirectional inhibition of both proteins' activities; Etk inhibition of p53 prevents BAK interaction with mitochondria and confers doxorubicin resistance.","method":"SH3 domain array screening, co-immunoprecipitation, kinase activity assay, siRNA knockdown, reporter gene assay (p53 transcriptional activity)","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — SH3 array identification validated by Co-IP, bidirectional activity assays, siRNA functional rescue, single lab with multiple orthogonal methods","pmids":["15355990"],"is_preprint":false},{"year":2004,"finding":"EGF treatment induces Etk tyrosine phosphorylation; Etk overexpression potentiates EGF-induced apoptosis associated with STAT1 activation; kinase-domain deletion mutant EtkΔK blocks EGF-induced STAT1 activation and apoptosis; conditionally activated Etk alone (independent of EGF) stimulates STAT1 and induces apoptosis.","method":"Adenovirus-mediated overexpression, dominant-negative mutant, conditional activation system (ΔEtk:ER fusion), EMSA, reporter gene assay, flow cytometry","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional activation system plus DN mutant plus EMSA, single lab","pmids":["14676838"],"is_preprint":false},{"year":2004,"finding":"Bmx is identified as a component of PKC-ε signaling complexes in cardiac tissue (functional proteomic analysis); Bmx is activated by nitric oxide in the heart concomitant with the late phase of cardioprotection; NO donor-induced Bmx expression is blocked by PKC inhibitor chelerythrine.","method":"Functional proteomics of PKC-ε complexes, in vivo NO donor treatment in rabbits, PKC inhibitor chelerythrine","journal":"American journal of physiology. Heart and circulatory physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — proteomics-based complex identification plus pharmacological in vivo validation, single lab","pmids":["15191890"],"is_preprint":false},{"year":2006,"finding":"Pim-1 44 kDa isoform directly binds the SH3 domain of Etk/BMX via its N-terminal proline-rich motif, activating Etk kinase activity possibly by competing with p53; this interaction confers resistance to chemotherapeutic drugs in prostate cancer cells.","method":"Co-immunoprecipitation, GST-pulldown, kinase activity assay, drug resistance assay","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct binding shown by two independent methods (Co-IP and pulldown) with kinase activity readout, single lab","pmids":["16186805"],"is_preprint":false},{"year":2006,"finding":"Bmx is required for ischemia-mediated arteriogenesis and angiogenesis in vivo; Bmx-KO mice showed markedly reduced recovery after hindlimb ischemia while constitutively active Bmx transgenic mice showed enhanced recovery; bone marrow transplantation showed Bmx in bone marrow-derived cells plays a critical role in early ischemic tissue remodeling.","method":"Bmx genetic knockout and transgenic mice, hindlimb ischemia model, bone marrow transplantation, histological quantification of vessels","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO and constitutively active transgenic plus bone marrow transplantation, multiple functional and histological readouts","pmids":["16932810"],"is_preprint":false},{"year":2007,"finding":"Bmx is activated by tyrosine phosphorylation downstream of Src and PI3K in PTEN-deficient prostate cancer cells; Bmx associates with ErbB3 in LNCaP cells and heregulin-β1 enhances this interaction and Bmx activity; EGF stimulates a Bmx-EGFR interaction and rapidly increases Bmx kinase activity in a Src-dependent but PI3K-independent manner.","method":"Co-immunoprecipitation, siRNA knockdown, kinase activity assay, pharmacological inhibitors (Src, PI3K)","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus kinase assays plus siRNA knockdown, single lab","pmids":["17823122"],"is_preprint":false},{"year":2007,"finding":"Bmx regulates TLR4-induced IL-6 production in human macrophages by targeting the IL-6 3' UTR to increase mRNA stabilization via a p38 MAPK-independent pathway; Btk knockdown reduced TNF-α but not IL-6 production, demonstrating distinct roles.","method":"RNA interference, LPS stimulation, cytokine ELISA, mRNA stability assay","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNAi knockdown with mRNA stability assay differentiating Bmx from Btk, single lab","pmids":["18025155"],"is_preprint":false},{"year":2008,"finding":"BMX is required for TNF-, IL-1β-, and TLR agonist-induced IL-8 secretion; BMX acts downstream of or at the TAK1-TAB complex level; BMX membrane localization (via its PH domain) is required for IL-8 promoter regulation; genetic deletion of BMX protects from K/BxN serum-transfer arthritis, but kinase-inactive BMX knock-in did not protect, revealing a kinase-independent in vivo function.","method":"Transient depletion (siRNA), epistasis analysis with TAK1-TAB, PH domain mutants, myristylation rescue, Bmx KO mice and kinase-inactive knock-in, passive K/BxN arthritis model","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple complementary genetic approaches (KO, kinase-dead knock-in) with in vivo disease model and mechanistic epistasis","pmids":["21471444"],"is_preprint":false},{"year":2008,"finding":"BMX is associated with MyD88, FAK, and Mal in fibroblast-like synoviocytes (by co-immunoprecipitation); LPS and protein I/II induce phosphorylation of Etk/BMX and Mal via a FAK-dependent pathway; knockdown of Bmx or Mal inhibits IL-6 synthesis in response to LPS.","method":"Co-immunoprecipitation, siRNA knockdown, phosphorylation assays","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP showing complex plus siRNA functional validation, single lab","pmids":["18292575"],"is_preprint":false},{"year":2008,"finding":"BMX is activated by RGD integrin stimulation in adult cardiomyocytes and co-distributes with STAT3 in detergent-insoluble fractions in pressure-overloaded myocardium; BMX and STAT3 form a complex and are co-phosphorylated in vivo without accompanying JAK2 activation; dominant-negative c-Src failed to block RGD-stimulated STAT3 or BMX changes.","method":"In vivo pressure overload model (feline RVPO), RGD peptide stimulation of cardiomyocytes, subcellular fractionation, co-immunoprecipitation, dominant-negative adenovirus","journal":"International journal of biological sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo model with fractionation and Co-IP, dominant-negative epistasis, single lab","pmids":["18612371"],"is_preprint":false},{"year":2008,"finding":"Loss of Bmx prevents pressure overload-induced cardiac hypertrophy in mice; Bmx-KO mice were resistant to TAC-induced cardiac growth and preserved ejection fraction, establishing Bmx as a necessary mediator of pressure overload hypertrophic signaling.","method":"Bmx knockout mice, transverse aortic constriction (TAC) model, echocardiography, organ/cell-level hypertrophy quantification","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean genetic KO with defined in vivo functional phenotype (cardiac hypertrophy, ejection fraction), replicated across multiple readouts","pmids":["18988895"],"is_preprint":false},{"year":2008,"finding":"Clinical-stage irreversible EGFR inhibitors (e.g., CI-1033) potently and covalently inhibit Bmx by modifying Cys496 within the ATP-binding pocket.","method":"Biochemical kinase inhibition assay, sequence alignment, covalent modification analysis","journal":"Bioorganic & medicinal chemistry letters","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — direct biochemical demonstration of covalent modification at defined residue, single lab","pmids":["18667312"],"is_preprint":false},{"year":2010,"finding":"Etk/BMX directly interacts with the androgen receptor (AR) through its SH2 domain; this interaction prevents AR-Mdm2 association, stabilizing AR under androgen-depleted conditions; Etk overexpression increases AR tyrosine phosphorylation in prostate cancer cells.","method":"Co-immunoprecipitation, SH2 domain mapping, phosphorylation assay, androgen-depleted culture, siRNA knockdown","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct Co-IP with domain mapping and mechanistic consequence (AR stabilization), single lab","pmids":["20570899"],"is_preprint":false},{"year":2010,"finding":"Etk/BMX binds PAR1 via its PH domain to a seven-residue region (C378–S384) in the PAR1 C-tail; this binding enables subsequent Shc association; hPar1-7A mutant incapable of Etk binding is unable to drive invasion; Etk knockdown inhibits PAR1-induced cell migration.","method":"Antibody array, co-immunoprecipitation, domain-deletion and point mutants (Y/A PAR1), Matrigel invasion assay, siRNA knockdown","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — binding site mapped with mutants plus functional rescue/block, single lab","pmids":["20559570"],"is_preprint":false},{"year":2011,"finding":"BMX activates STAT3 in glioblastoma stem cells (GSCs) to maintain self-renewal and tumorigenic potential; BMX knockdown inhibits STAT3 activation and GSC transcription factor expression; constitutively active STAT3 rescues the effects of BMX knockdown, placing BMX upstream of STAT3.","method":"shRNA knockdown, constitutively active STAT3 rescue, intracranial tumor growth assay, neurosphere formation","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis (CA-STAT3 rescue of BMX KD), in vivo tumor model, multiple readouts","pmids":["21481791"],"is_preprint":false},{"year":2013,"finding":"BMX preferentially phosphorylates substrates with a priming phosphotyrosine at the -1 position (pYY motif); BMX phosphorylates FAK at Tyr577 subsequent to Src-mediated phosphorylation at Tyr576; BMX deficiency (RNAi or genetic KO in MEFs) markedly impairs FAK and insulin receptor kinase domain activation (pYY), as well as downstream Akt Thr308 phosphorylation.","method":"Positional scanning peptide library screening, in vitro kinase assay, RNAi, Bmx KO MEFs, Bmx KO mouse liver, phospho-specific antibodies","journal":"Science signaling","confidence":"High","confidence_rationale":"Tier 1 / Strong — substrate preference defined biochemically, validated in vitro and in multiple genetic KO models with orthogonal readouts","pmids":["23716717"],"is_preprint":false},{"year":2013,"finding":"BMX covalently modifies Cys496 in a selective and irreversible manner; structure-based drug design yielded BMX-IN-1 (irreversible inhibitor) with nanomolar potency against Tel-BMX-transformed cells; kinome profiling confirms selectivity.","method":"Structure-based drug design, kinome profiling, covalent modification assay, cell proliferation assay","journal":"ACS chemical biology","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — structure-based design confirming Cys496 as covalent site, single lab","pmids":["23594111"],"is_preprint":false},{"year":2015,"finding":"BMX associates with BAK in viable cells and phosphorylates a key tyrosine residue on BAK needed to maintain it in an inactive conformation; elevated BMX prevents BAK activation upon chemotherapy treatment; BMX silencing potentiates BAK activation and renders tumor cells hypersensitive to chemotherapeutic agents.","method":"Co-immunoprecipitation, kinase assay (BAK phosphorylation), siRNA knockdown, BAK activation assay, drug sensitivity assay","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct kinase-substrate relationship demonstrated (Co-IP + phosphorylation assay) with functional consequences validated by KD in multiple cancer lines","pmids":["25649765"],"is_preprint":false},{"year":2015,"finding":"Angiotensin II-induced cardiac hypertrophy is significantly reduced in Bmx KO and kinase-inactive Bmx knock-in mice; Ang II increases Bmx phosphorylation in endothelial cells; Bmx silencing inhibits downstream STAT3 signaling in endothelial cells; Bmx inactivation suppresses mTORC1 pathway activation by Ang II; human cardiac endothelial cells but not cardiomyocytes express abundant Bmx, indicating an endothelial-cardiomyocyte cross-talk mechanism.","method":"Bmx KO and kinase-inactive knock-in mice, Ang II infusion, genome-wide transcriptomics, Bmx siRNA in endothelial cells, mTORC1/STAT3 phosphorylation assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — two independent genetic models (KO and kinase-dead knock-in) plus transcriptomics and mechanistic signaling assays","pmids":["26430242"],"is_preprint":false},{"year":2016,"finding":"Phosphorylation of tyrosine 566 of the caspase-generated C-terminal BMX fragment relatively inhibits its proteasomal degradation via the N-end rule pathway; the cleaved BMX fragment has an N-terminal tryptophan that targets it for N-end rule degradation; pY566 is required for the pro-apoptotic function of the fragment.","method":"Metabolic stability assay, proteasome inhibitors, site-directed mutagenesis (Y566), caspase cleavage in PC3 cells, N-end rule reporter assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — mutagenesis and in-cell degradation assays establishing novel phospho-regulated proteolytic processing, single lab","pmids":["27601470"],"is_preprint":false},{"year":2018,"finding":"BMX bypasses SOCS3-mediated inhibition of JAK2 to maintain STAT3 activation in GSCs; ibrutinib disrupts BMX-mediated STAT3 activation in GSCs but not in neural progenitor cells (which lack BMX and dampen JAK2/STAT3 via SOCS3); ibrutinib inhibits GBM growth and potentiates radiotherapy.","method":"Ibrutinib pharmacological inhibition, SOCS3 expression analysis, JAK2/STAT3 phosphorylation assays, GSC vs. NPC comparison, intracranial tumor models","journal":"Science translational medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — mechanistic epistasis (BMX-SOCS3-JAK2-STAT3) validated pharmacologically and in genetic models with in vivo tumor experiments","pmids":["29848664"],"is_preprint":false},{"year":2018,"finding":"AR directly suppresses BMX gene expression by binding to the BMX gene; BMX expression rapidly increases following androgen deprivation; BMX contributes to CRPC by phosphorylating the pYY activation loop motif of multiple receptor tyrosine kinases; a BMX substrate-specific anti-pYpY antibody confirmed in vivo pYY substrate phosphorylation correlated with BMX expression.","method":"AR ChIP, androgen deprivation/castration models, cell line and xenograft CRPC models, BMX-IN-1 and ibrutinib treatment, phospho-specific antibody (anti-pYpY)","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP for direct AR regulation, xenograft in vivo validation, substrate antibody confirming in vivo substrate engagement","pmids":["30012673"],"is_preprint":false},{"year":2019,"finding":"BMX localizes to the nucleus of endothelial cells via its SH3 domain; nuclear BMX (but not cytoplasm-targeted BMX) promotes Vegfr2 promoter activity by associating with and potentially phosphorylating transcription factor Sp1, increasing Sp1 binding to the Vegfr2 promoter; kinase-inactive BMX-K445R fails to promote Vegfr2 transcription.","method":"siRNA knockdown, luciferase reporter assay, chromatin immunoprecipitation (ChIP), nuclear/cytoplasmic fractionation, NLS- and NES-tagged BMX constructs, kinase-inactive mutant","journal":"Journal of cellular and molecular medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP for Sp1 binding, nuclear vs. cytoplasmic targeted constructs, kinase-dead mutant, multiple orthogonal methods in single study","pmids":["31642192"],"is_preprint":false},{"year":2020,"finding":"BMX directly phosphorylates PAR1 and promotes its internalization and deactivation in endothelial cells; BMX loss increases thrombin-PAR1-mediated endothelial permeability 2- to 3-fold; PAR1 antagonist SCH79797 rescues BMX-KO-mediated vascular leakage in sepsis.","method":"BMX global KO mice, cecal ligation and puncture sepsis model, electric cell-substrate impedance sensing (ECIS), Miles assay, PAR1 phosphorylation and internalization assays, pharmacological PAR1 antagonist rescue","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO in vivo model plus direct PAR1 phosphorylation assay plus pharmacological rescue, multiple orthogonal methods","pmids":["31910739"],"is_preprint":false},{"year":2020,"finding":"X-ray crystal structure of BMX covalently inhibited at Cys496 was determined; the structure reveals key interactions with Lys445 (critical for ATP catalysis) and a DFG-out-like inactive conformation.","method":"X-ray crystallography, covalent inhibitor design, kinase selectivity profiling, molecular dynamics simulations","journal":"RSC chemical biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — first crystal structure of BMX covalent complex with direct structural validation of Cys496 binding and inactive conformation","pmids":["34458764"],"is_preprint":false},{"year":2023,"finding":"BMX directly interacts with 3βHSD1 and phosphorylates it at Tyr344; this Y344 phosphorylation is required for 3βHSD1 cellular activity and generation of androgen/estrogen biosynthetic intermediates; in vivo blockade of 3βHSD1 Y344 phosphorylation inhibits CRPC.","method":"Co-immunoprecipitation of BMX and 3βHSD1, phospho-specific assay for pY344, in vitro kinase assay, patient tissue analysis, in vivo CRPC mouse model","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct kinase-substrate relationship (Co-IP + specific phospho-site assay + in vivo validation), replicated in patient tissues and mouse model","pmids":["36647826"],"is_preprint":false},{"year":2021,"finding":"Fas interacts with BMX in adipocytes via the Tyr189 site of Fas and the SH2 domain of BMX; this Fas/BMX complex mediates TNF-α-induced NF-κB and MAPK pathway activation and inflammatory cytokine release in adipocytes.","method":"Co-immunoprecipitation, site-directed mutagenesis (Fas Tyr189, BMX SH2), cytokine ELISA, NF-κB/MAPK activation assays","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus mutagenesis identifying interaction sites, single lab","pmids":["34536556"],"is_preprint":false},{"year":2022,"finding":"In FLT3-ITD+ AML, hypoxia upregulates BMX in an HIF-dependent manner; BMX promotes AKT/mTOR and pSTAT5 signaling as a compensatory survival mechanism during FLT3 inhibition; pharmacological BMX inhibition or genetic KO reduces chemokine secretion and restores gilteritinib sensitivity.","method":"RNA-Seq of patient samples, murine FLT3-ITD model, in vitro hypoxia experiments, pharmacological BMX inhibition, CRISPR KO, signaling pathway assays (pSTAT5, pAKT)","journal":"Blood advances","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO and pharmacological inhibition with defined signaling readouts; HIF-dependent regulation shown in vitro and in vivo model","pmids":["35797240"],"is_preprint":false},{"year":2022,"finding":"VEGF-A signals through BMX to induce VCAM-1 expression in human aortic endothelial cells; ibrutinib blocks BMX activation by VEGF-A and eliminates VEGF-A-stimulated VCAM-1 expression; ibrutinib inhibits endothelial VCAM-1 and platelet deposition in atherosclerosis-prone nonhuman primate carotid arteries in vivo.","method":"Ibrutinib and pharmacologically distinct BMX inhibitors in HAECs, flow cytometry, contrast-enhanced ultrasound molecular imaging in vivo (nonhuman primate)","journal":"Cellular and molecular bioengineering","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple inhibitors in vitro plus in vivo imaging in primate model, mechanistic link between VEGF-A, BMX, and VCAM-1 established","pmids":["35611166"],"is_preprint":false}],"current_model":"BMX is a Tec-family nonreceptor tyrosine kinase that is activated downstream of PI3K (via PH-domain-mediated membrane translocation), Src, and multiple cell-surface receptors (TNFR2, Tie-2, VEGFR1/2, EGFR/ErbB3, IL-3R, G-CSFR); once active, it phosphorylates a priming-pY-dependent pYY motif to amplify multiple downstream RTKs (FAK, insulin receptor), directly phosphorylates and activates STAT transcription factors, BAK (holding it inactive), PAR1 (promoting internalization), 3βHSD1 (enabling androgen biosynthesis), and the adaptor Cas (linking it to Crk-dependent actin remodeling and migration); nuclear-localized BMX additionally transactivates VEGFR2 transcription via Sp1; caspase cleavage generates a hyperactive C-terminal fragment whose stability is modulated by N-end rule-dependent proteasomal degradation controlled by Tyr566 phosphorylation; and an irreversible covalent bond with Cys496 within the DFG-out ATP pocket is the mechanistic basis of inhibition by ibrutinib and EGFR inhibitors."},"narrative":{"mechanistic_narrative":"BMX (Etk) is a Tec-family nonreceptor tyrosine kinase, built from PH, SH3, SH2, and catalytic domains, that couples cell-surface receptor and PI3K signaling to cytoskeletal, survival, transcriptional, and angiogenic programs [PMID:7970727, PMID:9520419]. Its activation is gated by PI3K-dependent membrane translocation through its PH domain and by Src, downstream of a broad set of receptors including TNFR2, Tie-2/VEGFR1/2, EGFR/ErbB3, IL-3R, and G-CSFR [PMID:9520419, PMID:10962576, PMID:11416142, PMID:12370298, PMID:17823122]. Once active, BMX phosphorylates substrates bearing a priming phosphotyrosine in a pYY activation-loop motif, amplifying FAK and the insulin receptor and feeding into Akt signaling [PMID:23716717]. BMX directly activates STAT transcription factors independently of JAK to drive differentiation and tumor-cell self-renewal, and in glioblastoma stem cells it bypasses SOCS3-mediated JAK2 inhibition to sustain STAT3 [PMID:9373245, PMID:21481791, PMID:29848664]. Through its SH2 and PH domains BMX engages effectors that control migration and survival: it phosphorylates p130Cas to promote Cas-Crk complexes and membrane ruffling [PMID:12832404], phosphorylates BAK to hold it in an inactive conformation and confer chemoresistance [PMID:25649765], binds and stabilizes the androgen receptor while phosphorylating 3βHSD1 to enable androgen biosynthesis in castration-resistant prostate cancer [PMID:20570899, PMID:36647826], and phosphorylates PAR1 to drive its internalization and limit endothelial permeability [PMID:31910739]. In the endothelium BMX is a node in angiogenesis and arteriogenesis, required for ischemic vascular recovery and acting nuclearly via its SH3 domain to transactivate the Vegfr2 promoter through Sp1 [PMID:16932810, PMID:31642192]. BMX is also a necessary mediator of pressure-overload and angiotensin II-induced cardiac hypertrophy, in part through kinase-independent functions revealed by kinase-dead knock-in mice [PMID:21471444, PMID:18988895, PMID:26430242]. Caspase cleavage during apoptosis generates a hyperactive C-terminal fragment whose stability is set by Tyr566 phosphorylation acting on the N-end rule pathway [PMID:11278797, PMID:27601470]. A reactive Cys496 in the ATP pocket forms an irreversible covalent bond that is the structural basis for inhibition by ibrutinib and irreversible EGFR inhibitors, validated by crystallography of the inactive, DFG-out-like enzyme [PMID:18667312, PMID:23594111, PMID:34458764].","teleology":[{"year":1994,"claim":"Establishing that BMX is a bona fide enzyme: the cloned gene was shown to encode a multidomain (PH/SH3/SH2/kinase) nonreceptor tyrosine kinase with intrinsic catalytic activity.","evidence":"Transfection and immunoprecipitation of tyrosyl-phosphorylated BMX in COS and NIH3T3 cells","pmids":["7970727"],"confidence":"Medium","gaps":["No upstream activators or substrates identified","Domain functions not yet dissected"]},{"year":1998,"claim":"Defining the upstream gate: BMX was placed as a PI3K effector activated by PH-domain-mediated membrane recruitment, explaining how receptors funnel into BMX activation.","evidence":"Wortmannin inhibition, constitutively active p110 and dominant-negative p85 epistasis in IL-6-stimulated cells; later GFP membrane translocation imaging","pmids":["9520419","10962576"],"confidence":"High","gaps":["Some receptor inputs (EGFR) later shown PI3K-independent","Mechanism of membrane-induced conformational activation not resolved"]},{"year":1997,"claim":"Linking BMX to gene expression: it directly activates STAT1/3/5 DNA binding and STAT-dependent transcription independent of JAK, identifying a transcriptional output arm.","evidence":"EMSA, reporter assays, and PKC isoform co-expression in mammalian and insect cells","pmids":["9373245"],"confidence":"High","gaps":["Direct STAT phosphorylation by BMX vs. indirect not fully separated here","Physiological STAT targets context-dependent"]},{"year":1999,"claim":"Placing BMX in the conserved Tec-kinase signaling logic: it reconstitutes PLCγ2-dependent calcium and ERK signaling in Btk-null cells, defining a shared role as amplifier of receptor-proximal signal transduction.","evidence":"Genetic reconstitution in Btk-deficient DT40 B cells with calcium and ERK readouts","pmids":["10224128"],"confidence":"High","gaps":["Degree of functional redundancy with Btk/Tec in vivo unclear"]},{"year":2001,"claim":"Connecting BMX to migration and cytoskeletal machinery: it binds Pak1 via its PH domain and associates with cell-surface receptors (TNFR2, Tie-2, VEGFR1) and caveolin-1, embedding it in endothelial signaling complexes.","evidence":"Co-IP, GST-pulldown, in vitro kinase assays, receptor activation assays, and Bmx knockout/knock-in reporter mice","pmids":["11382770","12370298","11416142","11751885"],"confidence":"High","gaps":["Bmx KO mice initially showed no overt phenotype, implying redundancy","Stoichiometry and assembly order of receptor complexes unresolved"]},{"year":2003,"claim":"Defining migration substrates and a VEGF axis: BMX phosphorylates p130Cas to drive Cas-Crk complexes and ruffling, and engages in reciprocal transactivation with VEGFR2 with Tyr566 recruiting PI3K p85.","evidence":"Co-IP, colocalization at ruffles, phospho-site mutants, migration assays, and Etk-deficient endothelial cells","pmids":["12832404","14532277","12483534"],"confidence":"High","gaps":["Whether VEGF transactivation requires direct VEGFR2 phosphorylation by BMX not established"]},{"year":2004,"claim":"Establishing dual life/death control: BMX interacts with p53 via its SH3 domain to bidirectionally inhibit p53 and confer drug resistance, while EGF-activated BMX can also drive STAT1-dependent apoptosis.","evidence":"SH3 domain array, Co-IP, kinase and reporter assays, conditional activation systems","pmids":["15355990","14676838"],"confidence":"High","gaps":["Determinants of pro- vs. anti-apoptotic outcome context-dependent and unresolved"]},{"year":2006,"claim":"Identifying allosteric activators: Pim-1 binds the BMX SH3 domain to activate it, possibly by competing with p53, linking BMX activity state to chemoresistance.","evidence":"Co-IP, GST-pulldown, kinase and drug-resistance assays in prostate cancer cells","pmids":["16186805"],"confidence":"Medium","gaps":["Competition model with p53 inferred, not directly demonstrated","Single lab"]},{"year":2008,"claim":"Demonstrating in vivo vascular and inflammatory requirement: Bmx is required for ischemic arteriogenesis/angiogenesis and for receptor-induced inflammatory cytokine output, including a kinase-independent arthritis function.","evidence":"Bmx KO and constitutively active transgenic mice, hindlimb ischemia, bone marrow transplant; siRNA and TAK1-TAB epistasis with kinase-dead knock-in in K/BxN arthritis","pmids":["16932810","21471444","18025155","18292575"],"confidence":"High","gaps":["Mechanistic basis of kinase-independent in vivo function not defined","Cell-type-specific contributions only partly resolved"]},{"year":2008,"claim":"Establishing BMX as a cardiac hypertrophy mediator: loss of Bmx protects against pressure-overload hypertrophy, and BMX participates in PKC-ε/STAT3 cardioprotective complexes.","evidence":"Bmx KO mice with TAC and echocardiography; functional proteomics of PKC-ε complexes and RGD/STAT3 fractionation studies","pmids":["18988895","15191890","18612371"],"confidence":"High","gaps":["Cardiomyocyte vs. endothelial source of relevant BMX initially ambiguous","Downstream effectors in heart incompletely mapped"]},{"year":2010,"claim":"Mapping prostate-cancer effectors: BMX stabilizes AR via SH2-domain binding (blocking AR-Mdm2) and binds PAR1 via its PH domain to drive invasion.","evidence":"Co-IP, SH2/PH domain mapping, PAR1 point mutants, invasion and migration assays in androgen-depleted conditions","pmids":["20570899","20559570"],"confidence":"Medium","gaps":["Direct AR phosphorylation by BMX vs. binding-only stabilization not fully separated","Single lab for each interaction"]},{"year":2011,"claim":"Establishing a tumor stem-cell role: BMX maintains glioblastoma stem cell self-renewal by acting upstream of STAT3, with constitutively active STAT3 rescuing BMX loss.","evidence":"shRNA knockdown, CA-STAT3 rescue, neurosphere and intracranial tumor assays","pmids":["21481791"],"confidence":"High","gaps":["Receptor input activating BMX in GSCs not defined here"]},{"year":2013,"claim":"Defining substrate specificity rules: BMX recognizes a priming pYY motif and phosphorylates the FAK and insulin-receptor activation loops to amplify RTK signaling into Akt.","evidence":"Positional scanning peptide library, in vitro kinase assays, RNAi, Bmx KO MEFs and liver with phospho-specific antibodies","pmids":["23716717"],"confidence":"High","gaps":["Full physiological pYY substrate repertoire not enumerated"]},{"year":2015,"claim":"Mechanizing chemoresistance: BMX phosphorylates BAK to hold it inactive, so BMX silencing potentiates apoptosis; in parallel BMX is required for angiotensin II-driven cardiac hypertrophy through endothelial STAT3/mTORC1 signaling.","evidence":"Co-IP and BAK phosphorylation/activation assays with drug sensitivity; Bmx KO and kinase-dead knock-in mice with Ang II infusion and transcriptomics","pmids":["25649765","26430242"],"confidence":"High","gaps":["BAK tyrosine site identity and structural consequence not fully defined","Endothelial-to-cardiomyocyte cross-talk signal not molecularly identified"]},{"year":2016,"claim":"Resolving regulation of the apoptotic fragment: caspase cleavage yields a hyperactive C-terminal BMX with an N-terminal tryptophan, and Tyr566 phosphorylation stabilizes it against N-end rule degradation to enable its pro-apoptotic function.","evidence":"Metabolic stability assays, proteasome inhibitors, Y566 mutagenesis, N-end rule reporters in PC3 cells","pmids":["27601470","11278797"],"confidence":"Medium","gaps":["Upstream kinase for Tyr566 of the fragment not identified","Physiological contexts of fragment generation limited"]},{"year":2018,"claim":"Establishing a targeted therapeutic axis: AR directly represses BMX, so androgen deprivation derepresses BMX, which phosphorylates pYY motifs of multiple RTKs to drive castration-resistant prostate cancer; BMX also bypasses SOCS3 to sustain STAT3 in glioblastoma, sensitizing both to ibrutinib.","evidence":"AR ChIP, castration/xenograft models, anti-pYpY substrate antibody, BMX-IN-1 and ibrutinib; SOCS3/JAK2/STAT3 assays and intracranial GBM models","pmids":["30012673","29848664"],"confidence":"High","gaps":["Full set of RTKs amplified in CRPC not exhaustively defined"]},{"year":2019,"claim":"Discovering a nuclear transcriptional role: BMX enters the endothelial nucleus via its SH3 domain and transactivates the Vegfr2 promoter by acting on Sp1 in a kinase-dependent manner.","evidence":"NLS/NES-tagged and kinase-dead constructs, fractionation, luciferase reporters, and Sp1 ChIP","pmids":["31642192"],"confidence":"High","gaps":["Direct Sp1 phosphorylation by nuclear BMX shown only as potential","Nuclear import mechanism beyond SH3 dependence unresolved"]},{"year":2020,"claim":"Defining endothelial barrier and structural mechanism: BMX directly phosphorylates PAR1 to drive internalization and restrain vascular leakage, and the covalent Cys496 inhibitor complex was crystallized in a DFG-out-like inactive state.","evidence":"Bmx KO mice in CLP sepsis with ECIS, Miles assay, PAR1 phosphorylation and PAR1-antagonist rescue; X-ray crystallography with molecular dynamics","pmids":["31910739","34458764"],"confidence":"High","gaps":["Active-state BMX structure not determined","Reconciliation of PAR1 pro-invasive vs. barrier-protective roles across tissues incomplete"]},{"year":2023,"claim":"Adding a metabolic effector and disease links: BMX phosphorylates 3βHSD1 at Tyr344 to enable androgen biosynthesis in CRPC, and acts as a hypoxia/HIF-induced compensatory survival kinase in FLT3-ITD AML and a VEGF-A-driven mediator of endothelial VCAM-1 in atherosclerosis.","evidence":"Co-IP, pY344-specific and in vitro kinase assays, patient tissue and CRPC mouse models; CRISPR KO and inhibitors in AML; multiple BMX inhibitors and in vivo primate imaging in vascular models","pmids":["36647826","35797240","35611166","34536556"],"confidence":"High","gaps":["Direct receptor input upstream of BMX in AML hypoxia not fully defined","Adipocyte Fas/BMX inflammatory axis from single Medium-confidence study"]},{"year":null,"claim":"How BMX integrates its many receptor inputs, intramolecular regulation, and the choice between pro-survival and pro-apoptotic outputs in a given cell remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No active-state structure to explain receptor-specific activation modes","Logic determining BAK/STAT-driven survival vs. STAT1/fragment-driven apoptosis undefined","In vivo substrate repertoire incompletely mapped"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,15,31,33,39,41]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,1,31]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[1,30,38]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[2,6]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[16,28,33]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[2,6,12,23]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[38]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[16,25]},{"term_id":"GO:0005856","term_label":"cytoskeleton","supporting_discovery_ids":[15]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[2,14,31,36]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[22,23,24,42]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[11,16,17,33,35]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[30,36,37,41,43]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[1,30,38]}],"complexes":[],"partners":["STAT3","FAK","BCAR1","BAK1","TP53","AR","F2R","VEGFR2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P51813","full_name":"Cytoplasmic tyrosine-protein kinase BMX","aliases":["Bone marrow tyrosine kinase gene in chromosome X protein","Epithelial and endothelial tyrosine kinase","ETK","NTK38"],"length_aa":675,"mass_kda":78.0,"function":"Non-receptor tyrosine kinase that plays central but diverse modulatory roles in various signaling processes involved in the regulation of actin reorganization, cell migration, cell proliferation and survival, cell adhesion, and apoptosis. Participates in signal transduction stimulated by growth factor receptors, cytokine receptors, G-protein coupled receptors, antigen receptors and integrins. Induces tyrosine phosphorylation of BCAR1 in response to integrin regulation. Activation of BMX by integrins is mediated by PTK2/FAK1, a key mediator of integrin signaling events leading to the regulation of actin cytoskeleton and cell motility. Plays a critical role in TNF-induced angiogenesis, and implicated in the signaling of TEK and FLT1 receptors, 2 important receptor families essential for angiogenesis. Required for the phosphorylation and activation of STAT3, a transcription factor involved in cell differentiation. Also involved in interleukin-6 (IL6) induced differentiation. Also plays a role in programming adaptive cytoprotection against extracellular stress in different cell systems, salivary epithelial cells, brain endothelial cells, and dermal fibroblasts. May be involved in regulation of endocytosis through its interaction with an endosomal protein RUFY1. May also play a role in the growth and differentiation of hematopoietic cells; as well as in signal transduction in endocardial and arterial endothelial cells","subcellular_location":"Cytoplasm","url":"https://www.uniprot.org/uniprotkb/P51813/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/BMX","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/BMX","total_profiled":1310},"omim":[{"mim_id":"600583","title":"TEC PROTEIN TYROSINE KINASE; TEC","url":"https://www.omim.org/entry/600583"},{"mim_id":"600058","title":"PROTEIN TYROSINE KINASE TXK; TXK","url":"https://www.omim.org/entry/600058"},{"mim_id":"300101","title":"BONE MARROW KINASE, X-LINKED; BMX","url":"https://www.omim.org/entry/300101"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Plasma membrane","reliability":"Supported"},{"location":"Nucleoplasm","reliability":"Additional"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"epididymis","ntpm":96.9}],"url":"https://www.proteinatlas.org/search/BMX"},"hgnc":{"alias_symbol":["ETK","PSCTK3"],"prev_symbol":[]},"alphafold":{"accession":"P51813","domains":[{"cath_id":"2.30.29.30","chopping":"8-152","consensus_level":"high","plddt":89.3031,"start":8,"end":152},{"cath_id":"3.30.505.10","chopping":"294-392","consensus_level":"high","plddt":88.1189,"start":294,"end":392},{"cath_id":"3.30.200.20","chopping":"402-491","consensus_level":"high","plddt":81.1014,"start":402,"end":491},{"cath_id":"1.10.510.10","chopping":"496-672","consensus_level":"high","plddt":89.9752,"start":496,"end":672}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P51813","model_url":"https://alphafold.ebi.ac.uk/files/AF-P51813-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P51813-F1-predicted_aligned_error_v6.png","plddt_mean":75.75},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=BMX","jax_strain_url":"https://www.jax.org/strain/search?query=BMX"},"sequence":{"accession":"P51813","fasta_url":"https://rest.uniprot.org/uniprotkb/P51813.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P51813/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P51813"}},"corpus_meta":[{"pmid":"11340625","id":"PMC_11340625","title":"The Tec family of cytoplasmic tyrosine kinases: mammalian Btk, Bmx, Itk, Tec, Txk and homologs in other species.","date":"2001","source":"BioEssays : news and reviews in molecular, cellular and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/11340625","citation_count":238,"is_preprint":false},{"pmid":"21481791","id":"PMC_21481791","title":"Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3.","date":"2011","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/21481791","citation_count":231,"is_preprint":false},{"pmid":"9520419","id":"PMC_9520419","title":"Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3'-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells.","date":"1998","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9520419","citation_count":210,"is_preprint":false},{"pmid":"7970727","id":"PMC_7970727","title":"BMX, a novel nonreceptor tyrosine kinase gene of the BTK/ITK/TEC/TXK family located in chromosome Xp22.2.","date":"1994","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/7970727","citation_count":171,"is_preprint":false},{"pmid":"11713275","id":"PMC_11713275","title":"Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase.","date":"2001","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11713275","citation_count":157,"is_preprint":false},{"pmid":"14532277","id":"PMC_14532277","title":"Etk/Bmx transactivates vascular endothelial growth factor 2 and recruits phosphatidylinositol 3-kinase to mediate the tumor necrosis factor-induced angiogenic pathway.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14532277","citation_count":136,"is_preprint":false},{"pmid":"29848664","id":"PMC_29848664","title":"Ibrutinib inactivates BMX-STAT3 in glioma stem cells to impair malignant growth and radioresistance.","date":"2018","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29848664","citation_count":124,"is_preprint":false},{"pmid":"12370298","id":"PMC_12370298","title":"Etk/Bmx as a tumor necrosis factor receptor type 2-specific kinase: role in endothelial cell migration and angiogenesis.","date":"2002","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12370298","citation_count":114,"is_preprint":false},{"pmid":"9373245","id":"PMC_9373245","title":"The Bmx tyrosine kinase induces activation of the Stat signaling pathway, which is specifically inhibited by protein kinase Cdelta.","date":"1997","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/9373245","citation_count":100,"is_preprint":false},{"pmid":"16186805","id":"PMC_16186805","title":"The 44 kDa Pim-1 kinase directly interacts with tyrosine kinase Etk/BMX and protects human prostate cancer cells from apoptosis induced by chemotherapeutic drugs.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16186805","citation_count":99,"is_preprint":false},{"pmid":"11382770","id":"PMC_11382770","title":"Etk/Bmx tyrosine kinase activates Pak1 and regulates tumorigenicity of breast cancer cells.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11382770","citation_count":97,"is_preprint":false},{"pmid":"29304768","id":"PMC_29304768","title":"Long-term Lactobacillus rhamnosus BMX 54 application to restore a balanced vaginal ecosystem: a promising solution against HPV-infection.","date":"2018","source":"BMC infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/29304768","citation_count":97,"is_preprint":false},{"pmid":"9755164","id":"PMC_9755164","title":"Tec/Bmx non-receptor tyrosine kinases are involved in regulation of Rho and serum response factor by Galpha12/13.","date":"1998","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/9755164","citation_count":81,"is_preprint":false},{"pmid":"16932810","id":"PMC_16932810","title":"Critical function of Bmx/Etk in ischemia-mediated arteriogenesis and angiogenesis.","date":"2006","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/16932810","citation_count":75,"is_preprint":false},{"pmid":"11416142","id":"PMC_11416142","title":"Bmx tyrosine kinase has a redundant function downstream of angiopoietin and vascular endothelial growth factor receptors in arterial endothelium.","date":"2001","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11416142","citation_count":71,"is_preprint":false},{"pmid":"9323053","id":"PMC_9323053","title":"Bmx tyrosine kinase is specifically expressed in the endocardium and the endothelium of large arteries.","date":"1997","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/9323053","citation_count":68,"is_preprint":false},{"pmid":"10362360","id":"PMC_10362360","title":"Etk/Bmx, a PH-domain containing tyrosine kinase, protects prostate cancer cells from apoptosis induced by photodynamic therapy or thapsigargin.","date":"1999","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10362360","citation_count":66,"is_preprint":false},{"pmid":"12483534","id":"PMC_12483534","title":"Coordinating Etk/Bmx activation and VEGF upregulation to promote cell survival and proliferation.","date":"2002","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12483534","citation_count":56,"is_preprint":false},{"pmid":"18025155","id":"PMC_18025155","title":"Bmx tyrosine kinase regulates TLR4-induced IL-6 production in human macrophages independently of p38 MAPK and NFkapp}B activity.","date":"2007","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/18025155","citation_count":56,"is_preprint":false},{"pmid":"20570899","id":"PMC_20570899","title":"Compensatory upregulation of tyrosine kinase Etk/BMX in response to androgen deprivation promotes castration-resistant growth of prostate cancer cells.","date":"2010","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/20570899","citation_count":56,"is_preprint":false},{"pmid":"12832404","id":"PMC_12832404","title":"p130Cas Couples the tyrosine kinase Bmx/Etk with regulation of the actin cytoskeleton and cell migration.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12832404","citation_count":53,"is_preprint":false},{"pmid":"10224128","id":"PMC_10224128","title":"Reconstitution of Btk signaling by the atypical tec family tyrosine kinases Bmx and Txk.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10224128","citation_count":52,"is_preprint":false},{"pmid":"11751885","id":"PMC_11751885","title":"Functional interaction of caveolin-1 with Bruton's tyrosine kinase and Bmx.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11751885","citation_count":48,"is_preprint":false},{"pmid":"31910739","id":"PMC_31910739","title":"BMX Represses Thrombin-PAR1-Mediated Endothelial Permeability and Vascular Leakage During Early Sepsis.","date":"2020","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/31910739","citation_count":45,"is_preprint":false},{"pmid":"16912182","id":"PMC_16912182","title":"Tyrosine kinase Etk/BMX is up-regulated in human prostate cancer and its overexpression induces prostate intraepithelial neoplasia in mouse.","date":"2006","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16912182","citation_count":44,"is_preprint":false},{"pmid":"23594111","id":"PMC_23594111","title":"Discovery of a selective irreversible BMX inhibitor for prostate cancer.","date":"2013","source":"ACS chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/23594111","citation_count":42,"is_preprint":false},{"pmid":"22449076","id":"PMC_22449076","title":"BMX and its role in inflammation, cardiovascular disease, and cancer.","date":"2012","source":"International reviews of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22449076","citation_count":41,"is_preprint":false},{"pmid":"15788485","id":"PMC_15788485","title":"Etk/Bmx mediates expression of stress-induced adaptive genes VEGF, PAI-1, and iNOS via multiple signaling cascades in different cell systems.","date":"2005","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/15788485","citation_count":38,"is_preprint":false},{"pmid":"29227282","id":"PMC_29227282","title":"Hypoxia-induced upregulation of BMX kinase mediates therapeutic resistance in acute myeloid leukemia.","date":"2017","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/29227282","citation_count":37,"is_preprint":false},{"pmid":"9373244","id":"PMC_9373244","title":"Predominant expression of murine Bmx tyrosine kinase in the granulo-monocytic lineage.","date":"1997","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/9373244","citation_count":37,"is_preprint":false},{"pmid":"10962576","id":"PMC_10962576","title":"The Bmx tyrosine kinase is activated by IL-3 and G-CSF in a PI-3K dependent manner.","date":"2000","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10962576","citation_count":37,"is_preprint":false},{"pmid":"27101199","id":"PMC_27101199","title":"EPHA3 regulates the multidrug resistance of small cell lung cancer via the PI3K/BMX/STAT3 signaling pathway.","date":"2016","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27101199","citation_count":37,"is_preprint":false},{"pmid":"26430242","id":"PMC_26430242","title":"Endothelial Bmx tyrosine kinase activity is essential for myocardial hypertrophy and remodeling.","date":"2015","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/26430242","citation_count":36,"is_preprint":false},{"pmid":"15355990","id":"PMC_15355990","title":"Bi-directional regulation between tyrosine kinase Etk/BMX and tumor suppressor p53 in response to DNA damage.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15355990","citation_count":36,"is_preprint":false},{"pmid":"18667312","id":"PMC_18667312","title":"Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase.","date":"2008","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/18667312","citation_count":33,"is_preprint":false},{"pmid":"21471444","id":"PMC_21471444","title":"The tyrosine kinase BMX is an essential mediator of inflammatory arthritis in a kinase-independent manner.","date":"2011","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/21471444","citation_count":32,"is_preprint":false},{"pmid":"18292575","id":"PMC_18292575","title":"Etk/BMX, a Btk family tyrosine kinase, and Mal contribute to the cross-talk between MyD88 and FAK pathways.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18292575","citation_count":32,"is_preprint":false},{"pmid":"34072831","id":"PMC_34072831","title":"NBM-BMX, an HDAC8 Inhibitor, Overcomes Temozolomide Resistance in Glioblastoma Multiforme by Downregulating the β-Catenin/c-Myc/SOX2 Pathway and Upregulating p53-Mediated MGMT Inhibition.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34072831","citation_count":32,"is_preprint":false},{"pmid":"25649765","id":"PMC_25649765","title":"BMX Negatively Regulates BAK Function, Thereby Increasing Apoptotic Resistance to Chemotherapeutic Drugs.","date":"2015","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/25649765","citation_count":32,"is_preprint":false},{"pmid":"14676838","id":"PMC_14676838","title":"The role of tyrosine kinase Etk/Bmx in EGF-induced apoptosis of MDA-MB-468 breast cancer cells.","date":"2004","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/14676838","citation_count":32,"is_preprint":false},{"pmid":"17823122","id":"PMC_17823122","title":"Activation of nonreceptor tyrosine kinase Bmx/Etk mediated by phosphoinositide 3-kinase, epidermal growth factor receptor, and ErbB3 in prostate cancer cells.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17823122","citation_count":31,"is_preprint":false},{"pmid":"27197306","id":"PMC_27197306","title":"Inhibition of PI3K/BMX Cell Survival Pathway Sensitizes to BH3 Mimetics in SCLC.","date":"2016","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/27197306","citation_count":30,"is_preprint":false},{"pmid":"28514765","id":"PMC_28514765","title":"BMX/Etk promotes cell proliferation and tumorigenicity of cervical cancer cells through PI3K/AKT/mTOR and STAT3 pathways.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28514765","citation_count":30,"is_preprint":false},{"pmid":"18612371","id":"PMC_18612371","title":"STAT3 activation in pressure-overloaded feline myocardium: role for integrins and the tyrosine kinase BMX.","date":"2008","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/18612371","citation_count":30,"is_preprint":false},{"pmid":"15229285","id":"PMC_15229285","title":"Bmx tyrosine kinase transgene induces skin hyperplasia, inflammatory angiogenesis, and accelerated wound healing.","date":"2004","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/15229285","citation_count":29,"is_preprint":false},{"pmid":"8790141","id":"PMC_8790141","title":"BMX tyrosine kinase gene is expressed in granulocytes and myeloid leukaemias.","date":"1996","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/8790141","citation_count":28,"is_preprint":false},{"pmid":"2832730","id":"PMC_2832730","title":"Transcriptional properties of BmX, a moderately repetitive silkworm gene that is an RNA polymerase III template.","date":"1988","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/2832730","citation_count":28,"is_preprint":false},{"pmid":"30012673","id":"PMC_30012673","title":"BMX-Mediated Regulation of Multiple Tyrosine Kinases Contributes to Castration Resistance in Prostate Cancer.","date":"2018","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/30012673","citation_count":27,"is_preprint":false},{"pmid":"19161832","id":"PMC_19161832","title":"Phylogeny of Tec family kinases identification of a premetazoan origin of Btk, Bmx, Itk, Tec, Txk, and the Btk regulator SH3BP5.","date":"2008","source":"Advances in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19161832","citation_count":27,"is_preprint":false},{"pmid":"27601470","id":"PMC_27601470","title":"Phosphorylation Impacts N-end Rule Degradation of the Proteolytically Activated Form of BMX Kinase.","date":"2016","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27601470","citation_count":27,"is_preprint":false},{"pmid":"28401017","id":"PMC_28401017","title":"miR-495 promotes the chemoresistance of SCLC through the epithelial-mesenchymal transition via Etk/BMX.","date":"2017","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/28401017","citation_count":27,"is_preprint":false},{"pmid":"11278797","id":"PMC_11278797","title":"Proteolytic activation of ETK/Bmx tyrosine kinase by caspases.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11278797","citation_count":27,"is_preprint":false},{"pmid":"22593188","id":"PMC_22593188","title":"Deletion of the endothelial Bmx tyrosine kinase decreases tumor angiogenesis and growth.","date":"2012","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/22593188","citation_count":26,"is_preprint":false},{"pmid":"20559570","id":"PMC_20559570","title":"Etk/Bmx regulates proteinase-activated-receptor1 (PAR1) in breast cancer invasion: signaling partners, hierarchy and physiological significance.","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/20559570","citation_count":26,"is_preprint":false},{"pmid":"23198769","id":"PMC_23198769","title":"Mini-review: bmx kinase inhibitors for cancer therapy.","date":"2013","source":"Recent patents on anti-cancer drug discovery","url":"https://pubmed.ncbi.nlm.nih.gov/23198769","citation_count":24,"is_preprint":false},{"pmid":"24709422","id":"PMC_24709422","title":"BMX acts downstream of PI3K to promote colorectal cancer cell survival and pathway inhibition sensitizes to the BH3 mimetic ABT-737.","date":"2014","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/24709422","citation_count":24,"is_preprint":false},{"pmid":"23716717","id":"PMC_23716717","title":"Tyrosine kinase BMX phosphorylates phosphotyrosine-primed motif mediating the activation of multiple receptor tyrosine kinases.","date":"2013","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/23716717","citation_count":23,"is_preprint":false},{"pmid":"31728872","id":"PMC_31728872","title":"BMX activates Wnt/β-catenin signaling pathway to promote cell proliferation and migration in breast cancer.","date":"2019","source":"Breast cancer (Tokyo, Japan)","url":"https://pubmed.ncbi.nlm.nih.gov/31728872","citation_count":23,"is_preprint":false},{"pmid":"18196928","id":"PMC_18196928","title":"Expression of tyrosine kinase Etk/Bmx and its relationship with AP-1- and NF-kappaB-associated proteins in hepatocellular carcinoma.","date":"2008","source":"Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/18196928","citation_count":23,"is_preprint":false},{"pmid":"36647826","id":"PMC_36647826","title":"BMX controls 3βHSD1 and sex steroid biosynthesis in cancer.","date":"2023","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/36647826","citation_count":22,"is_preprint":false},{"pmid":"24606948","id":"PMC_24606948","title":"The expression and role of tyrosine kinase ETK/BMX in renal cell carcinoma.","date":"2014","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/24606948","citation_count":21,"is_preprint":false},{"pmid":"36628607","id":"PMC_36628607","title":"The X-linked Becker muscular dystrophy (bmx) mouse models Becker muscular dystrophy via deletion of murine dystrophin exons 45-47.","date":"2023","source":"Journal of cachexia, sarcopenia and muscle","url":"https://pubmed.ncbi.nlm.nih.gov/36628607","citation_count":21,"is_preprint":false},{"pmid":"18988895","id":"PMC_18988895","title":"Loss of Bmx nonreceptor tyrosine kinase prevents pressure overload-induced cardiac hypertrophy.","date":"2008","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/18988895","citation_count":21,"is_preprint":false},{"pmid":"33291717","id":"PMC_33291717","title":"Discovery of a Novel Class of Covalent Dual Inhibitors Targeting the Protein Kinases BMX and BTK.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33291717","citation_count":20,"is_preprint":false},{"pmid":"34536556","id":"PMC_34536556","title":"Fas signaling in adipocytes promotes low-grade inflammation and lung metastasis of colorectal cancer through interaction with Bmx.","date":"2021","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/34536556","citation_count":20,"is_preprint":false},{"pmid":"18402776","id":"PMC_18402776","title":"Bmx regulates LPS-induced IL-6 and VEGF production via mRNA stability in rheumatoid synovial fibroblasts.","date":"2008","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/18402776","citation_count":20,"is_preprint":false},{"pmid":"26065336","id":"PMC_26065336","title":"NBM-T-BMX-OS01, an Osthole Derivative, Sensitizes Human Lung Cancer A549 Cells to Cisplatin through AMPK-Dependent Inhibition of ERK and Akt Pathway.","date":"2015","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/26065336","citation_count":19,"is_preprint":false},{"pmid":"27709295","id":"PMC_27709295","title":"Topically applied manganese-porphyrins BMX-001 and BMX-010 display a significant anti-inflammatory response in a mouse model of allergic dermatitis.","date":"2016","source":"Archives of dermatological research","url":"https://pubmed.ncbi.nlm.nih.gov/27709295","citation_count":18,"is_preprint":false},{"pmid":"31130822","id":"PMC_31130822","title":"BMX-ARHGAP fusion protein maintains the tumorigenicity of gastric cancer stem cells by activating the JAK/STAT3 signaling pathway.","date":"2019","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/31130822","citation_count":18,"is_preprint":false},{"pmid":"24312323","id":"PMC_24312323","title":"Anti-cancer activity of an osthole derivative, NBM-T-BMX-OS01: targeting vascular endothelial growth factor receptor signaling and angiogenesis.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24312323","citation_count":18,"is_preprint":false},{"pmid":"27602372","id":"PMC_27602372","title":"Current understanding of tyrosine kinase BMX in inflammation and its inhibitors.","date":"2014","source":"Burns & trauma","url":"https://pubmed.ncbi.nlm.nih.gov/27602372","citation_count":17,"is_preprint":false},{"pmid":"11350762","id":"PMC_11350762","title":"Etk/Bmx activation modulates barrier function in epithelial cells.","date":"2001","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/11350762","citation_count":16,"is_preprint":false},{"pmid":"28140585","id":"PMC_28140585","title":"Discovery of 2-((3-Acrylamido-4-methylphenyl)amino)-N-(2-methyl-5-(3,4,5-trimethoxybenzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-BMX-078) as a Highly Potent and Selective Type II Irreversible Bone Marrow Kinase in the X Chromosome (BMX) Kinase Inhibitor.","date":"2017","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28140585","citation_count":15,"is_preprint":false},{"pmid":"21339702","id":"PMC_21339702","title":"Tyrosine kinase Etk/BMX protects nasopharyngeal carcinoma cells from apoptosis induced by radiation.","date":"2011","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/21339702","citation_count":14,"is_preprint":false},{"pmid":"25499959","id":"PMC_25499959","title":"Identification of a novel gene fusion (BMX-ARHGAP) in gastric cardia adenocarcinoma.","date":"2014","source":"Diagnostic pathology","url":"https://pubmed.ncbi.nlm.nih.gov/25499959","citation_count":12,"is_preprint":false},{"pmid":"37534133","id":"PMC_37534133","title":"Vamorolone improves Becker muscular dystrophy and increases dystrophin protein in bmx model mice.","date":"2023","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/37534133","citation_count":12,"is_preprint":false},{"pmid":"15191890","id":"PMC_15191890","title":"Bmx, a member of the Tec family of nonreceptor tyrosine kinases, is a novel participant in pharmacological cardioprotection.","date":"2004","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/15191890","citation_count":12,"is_preprint":false},{"pmid":"24860816","id":"PMC_24860816","title":"The influence of BMX gene polymorphisms on clinical symptoms after mild traumatic brain injury.","date":"2014","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/24860816","citation_count":11,"is_preprint":false},{"pmid":"23606881","id":"PMC_23606881","title":"NBM-T-L-BMX-OS01, Semisynthesized from Osthole, Is a Novel Inhibitor of Histone Deacetylase and Enhances Learning and Memory in Rats.","date":"2013","source":"Evidence-based complementary and alternative medicine : eCAM","url":"https://pubmed.ncbi.nlm.nih.gov/23606881","citation_count":11,"is_preprint":false},{"pmid":"35611166","id":"PMC_35611166","title":"Ibrutinib Inhibits BMX-Dependent Endothelial VCAM-1 Expression In Vitro and Pro-Atherosclerotic Endothelial Activation and Platelet Adhesion In Vivo.","date":"2022","source":"Cellular and molecular bioengineering","url":"https://pubmed.ncbi.nlm.nih.gov/35611166","citation_count":10,"is_preprint":false},{"pmid":"36575468","id":"PMC_36575468","title":"BMX, a specific HDAC8 inhibitor, with TMZ for advanced CRC therapy: a novel synergic effect to elicit p53-, β-catenin- and MGMT-dependent apoptotic cell death.","date":"2022","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/36575468","citation_count":10,"is_preprint":false},{"pmid":"35797240","id":"PMC_35797240","title":"BMX kinase mediates gilteritinib resistance in FLT3-mutated AML through microenvironmental factors.","date":"2022","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/35797240","citation_count":9,"is_preprint":false},{"pmid":"21929872","id":"PMC_21929872","title":"Suppression of Etk/Bmx protects against ischemic brain injury.","date":"2011","source":"Cell transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/21929872","citation_count":9,"is_preprint":false},{"pmid":"28734581","id":"PMC_28734581","title":"Discovery of (R)-5-(benzo[d][1,3]dioxol-5-yl)-7-((1-(vinylsulfonyl)pyrrolidin-2-yl)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (B6) as a potent Bmx inhibitor for the treatment of NSCLC.","date":"2017","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/28734581","citation_count":9,"is_preprint":false},{"pmid":"15207703","id":"PMC_15207703","title":"Bmx is a downstream Rap1 effector in VEGF-induced endothelial cell activation.","date":"2004","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/15207703","citation_count":9,"is_preprint":false},{"pmid":"34458764","id":"PMC_34458764","title":"Structural and biophysical insights into the mode of covalent binding of rationally designed potent BMX inhibitors.","date":"2020","source":"RSC chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/34458764","citation_count":9,"is_preprint":false},{"pmid":"34813779","id":"PMC_34813779","title":"CHMFL-BMX-078, a BMX inhibitor, overcomes the resistance of melanoma to vemurafenib via inhibiting AKT pathway.","date":"2021","source":"Chemico-biological interactions","url":"https://pubmed.ncbi.nlm.nih.gov/34813779","citation_count":8,"is_preprint":false},{"pmid":"30216523","id":"PMC_30216523","title":"Suppression of BMX-ARHGAP fusion gene inhibits epithelial-mesenchymal transition in gastric cancer cells via RhoA-mediated blockade of JAK/STAT axis.","date":"2018","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30216523","citation_count":8,"is_preprint":false},{"pmid":"21861773","id":"PMC_21861773","title":"Ligand-independent activation of the arylhydrocarbon receptor by ETK (Bmx) tyrosine kinase helps MCF10AT1 breast cancer cells to survive in an apoptosis-inducing environment.","date":"2011","source":"Biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21861773","citation_count":8,"is_preprint":false},{"pmid":"28422715","id":"PMC_28422715","title":"A novel BMX variant promotes tumor cell growth and migration in lung adenocarcinoma.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28422715","citation_count":7,"is_preprint":false},{"pmid":"31642192","id":"PMC_31642192","title":"Nuclear localization of the tyrosine kinase BMX mediates VEGFR2 expression.","date":"2019","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31642192","citation_count":6,"is_preprint":false},{"pmid":"33244276","id":"PMC_33244276","title":"Lactobacillus rhamnosus BMX 54 + Lactose, A Symbiotic Long-Lasting Vaginal Approach to Improve Women's Health.","date":"2020","source":"International journal of women's health","url":"https://pubmed.ncbi.nlm.nih.gov/33244276","citation_count":6,"is_preprint":false},{"pmid":"24785188","id":"PMC_24785188","title":"Sodium and potassium regulate endothelial phospholipase C-γ and Bmx.","date":"2014","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/24785188","citation_count":5,"is_preprint":false},{"pmid":"16458122","id":"PMC_16458122","title":"Expression of Etk/Bmx tyrosine kinase in the tumorigenicity of nasopharyngeal epithelium and its relation with EB virus infection and the apoptosis-related protein Bcl-2.","date":"2006","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/16458122","citation_count":5,"is_preprint":false},{"pmid":"40230692","id":"PMC_40230692","title":"Machine learning-based transcriptmics analysis reveals BMX, GRB10, and GADD45A as crucial biomarkers and therapeutic targets in sepsis.","date":"2025","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/40230692","citation_count":4,"is_preprint":false},{"pmid":"18270973","id":"PMC_18270973","title":"Expression of Etk/Bmx tyrosine kinase in intrahepatic cholangiocarcinoma.","date":"2008","source":"Journal of surgical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/18270973","citation_count":4,"is_preprint":false},{"pmid":"25756192","id":"PMC_25756192","title":"BMX: a tool for computing bacterial phyletic composition from orthologous maps.","date":"2015","source":"BMC research notes","url":"https://pubmed.ncbi.nlm.nih.gov/25756192","citation_count":4,"is_preprint":false},{"pmid":"40663577","id":"PMC_40663577","title":"Identification and experimental validation of BMX as a crucial PANoptosis‑related gene for immune response in Spinal Cord Injury.","date":"2025","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/40663577","citation_count":3,"is_preprint":false},{"pmid":"39133652","id":"PMC_39133652","title":"Preclinical spheroid models identify BMX as a therapeutic target for metastatic MYCN nonamplified neuroblastoma.","date":"2024","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/39133652","citation_count":2,"is_preprint":false},{"pmid":"38434304","id":"PMC_38434304","title":"BMX deletion mitigates neuroinflammation induced by retinal ischemia/reperfusion through modulation of the AKT/ERK/STAT3 signaling cascade.","date":"2024","source":"Heliyon","url":"https://pubmed.ncbi.nlm.nih.gov/38434304","citation_count":2,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50922,"output_tokens":10871,"usd":0.157915,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":21779,"output_tokens":6500,"usd":0.135697,"stage2_stop_reason":"end_turn"},"total_usd":0.293612,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1994,\n      \"finding\": \"BMX encodes a nonreceptor tyrosine kinase containing PH, SH3, SH2, and catalytic domains; immunoprecipitates of COS cells transfected with BMX and NIH3T3 cells expressing a BMX retrovirus contained a tyrosyl-phosphorylated BMX polypeptide, demonstrating intrinsic kinase activity.\",\n      \"method\": \"Transfection, immunoprecipitation, tyrosine phosphorylation assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct in-cell kinase activity demonstration with multiple cell systems in the original cloning paper\",\n      \"pmids\": [\"7970727\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"BMX induces tyrosine phosphorylation and DNA-binding activity of STAT1, STAT3, and STAT5, and activates STAT1- and STAT5-dependent transcriptional reporter genes, independent of JAK kinase activation; this BMX-mediated STAT activation is specifically inhibited by PKCδ but not PKCβ1, PKCε, or PKCζ.\",\n      \"method\": \"Transient transfection in mammalian and insect cells, EMSA, reporter gene assay, co-expression with PKC isoforms\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (EMSA, reporter assay, phosphorylation), replicated across mammalian and insect cell systems\",\n      \"pmids\": [\"9373245\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"BMX (Etk) is an effector of PI3-kinase: wortmannin blocked IL-6-induced Etk activation, constitutively active p110 activated Etk in absence of IL-6, and dominant-negative p85 blocked IL-6-induced activation; IL-6-induced neuroendocrine differentiation of LNCaP prostate cancer cells was abrogated by dominant-negative Etk.\",\n      \"method\": \"Pharmacological inhibition (wortmannin), dominant-negative/constitutively active PI3K subunit overexpression, cellular differentiation assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — three independent epistasis approaches (inhibitor, CA p110, DN p85) converging on same conclusion\",\n      \"pmids\": [\"9520419\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"BMX and Tec activate serum response factor (SRF) in synergy with constitutively active Gα12/13, in a Rho-dependent manner (C3-sensitive); kinase and TH domains of BMX are required for SRF activation; kinase-deficient Bmx inhibits Gα12/13- and thrombin-induced SRF activation.\",\n      \"method\": \"Transient transfection, reporter gene assay, C3 toxin treatment, dominant-negative mutant expression\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple domain mutants, pharmacological blockade, and dominant-negative approaches in a single study\",\n      \"pmids\": [\"9755164\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"BMX reconstituted PLCγ2-dependent signaling (calcium mobilization, ERK/MAPK activation, apoptosis) in Btk-deficient DT40 B cells, demonstrating a common Tec-kinase role as amplifier of PLCγ2-dependent signal transduction.\",\n      \"method\": \"Genetic reconstitution in Btk-deficient DT40 cells, calcium flux assay, ERK activation assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — genetic reconstitution in defined null background with multiple readouts\",\n      \"pmids\": [\"10224128\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Etk/BMX protects prostate cancer cells from apoptosis induced by PDT or thapsigargin; PI3K inhibitor LY294002 abolished Etk activity and increased apoptosis; dominant-negative Etk increased apoptosis, while Etk overexpression reduced it.\",\n      \"method\": \"Overexpression/dominant-negative Etk in LNCaP cells, pharmacological PI3K inhibition, PARP cleavage assay, DNA fragmentation\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss- and gain-of-function with pharmacological validation, single lab\",\n      \"pmids\": [\"10362360\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"BMX is catalytically activated by IL-3 and G-CSF receptors in a PI3K-dependent manner; GFP-tagged Bmx translocated to cellular membranes upon co-expression of constitutively active PI3K; overexpression of wild-type Bmx in 32D cells induced apoptosis with G-CSF, while kinase-dead Bmx allowed granulocytic differentiation.\",\n      \"method\": \"Kinase activity assay, GFP-live cell imaging/membrane translocation, PI3K inhibitors, overexpression of WT vs. kinase-dead Bmx in myeloid progenitor cells\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — membrane translocation directly observed, multiple complementary functional readouts, PI3K-dependence confirmed pharmacologically\",\n      \"pmids\": [\"10962576\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Etk/BMX directly associates with Pak1 via its N-terminal PH domain and phosphorylates Pak1 on tyrosine residues; this interaction was demonstrated by coimmunoprecipitation and GST-pulldown; Etk expression increased proliferation and anchorage-independent growth in breast cancer cells.\",\n      \"method\": \"Transient transfection, co-immunoprecipitation, GST-pulldown, in vitro kinase assay, anchorage-independent growth assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct binding (reciprocal Co-IP and pulldown) plus in vitro kinase assay showing phosphorylation of Pak1, single lab\",\n      \"pmids\": [\"11382770\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Etk/BMX is required for neuropeptide (bombesin/neurotensin)-induced androgen-independent growth of LNCaP prostate cancer cells; Etk activation requires FAK and Src but not PI3K; dominant-negative Etk blocks bombesin-induced growth and AR activation.\",\n      \"method\": \"Dominant-negative kinase overexpression, reporter gene assay (PSA promoter/ARE), AR transactivation assay\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epistasis established using dominant negatives for FAK, Src, and Etk; single lab\",\n      \"pmids\": [\"11713275\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Native BMX associates with endogenous caveolin-1 in primary human umbilical vein endothelial cells; caveolin-1 expression reduces tyrosine phosphorylation of BMX/Btk family members; caveolin-1 scaffolding peptide suppresses the autokinase activity of purified recombinant Btk (functional model for BMX).\",\n      \"method\": \"Co-immunoprecipitation of endogenous proteins in HUVECs, transient transfection, in vitro kinase assay with caveolin-1 scaffolding peptide\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — endogenous Co-IP in HUVECs for Bmx-caveolin-1; single lab, autokinase suppression shown in vitro for Btk as functional model\",\n      \"pmids\": [\"11751885\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Bmx is expressed downstream of Tie-2 and VEGFR-1 in arterial endothelial cells; activated Tie-2 induced tyrosyl phosphorylation of Bmx protein and both Tie-2 and VEGFR-1 stimulated Bmx tyrosine kinase activity; Bmx knockout mice were viable without obvious phenotype, indicating a redundant role.\",\n      \"method\": \"Bmx knock-in/knockout mice (lacZ reporter), receptor activation assays, kinase activity assay\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo genetic model combined with direct kinase activity measurements downstream of defined receptors\",\n      \"pmids\": [\"11416142\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Etk/BMX is proteolytically cleaved by caspases during apoptosis, generating a C-terminal fragment (containing SH2 and kinase domains) with ~4-fold higher kinase activity than full-length Etk; ectopic expression of this fragment sensitized PC3 cells to apoptosis.\",\n      \"method\": \"In vitro translation with [35S]-methionine, incubation with recombinant caspases/apoptotic extracts, in vitro kinase assay, ectopic expression in PC3 cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with recombinant caspases, direct kinase activity measurement, functional validation in cells\",\n      \"pmids\": [\"11278797\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Etk/BMX forms a preexisting complex with TNFR2 in a ligand-independent manner through multiple Etk domains (PH, TH, SH2) and the C-terminal 16 amino acids of TNFR2; TNF activates Etk specifically through TNFR2 (not TNFR1); constitutively active Etk enhanced TNF-induced EC migration and tube formation while dominant-negative Etk blocked these.\",\n      \"method\": \"Co-immunoprecipitation, TNFR2-specific agonist, TNFR2-deficient cells, domain-deletion mutants, cell migration/tube formation assay\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — receptor-specific epistasis using KO cells plus Co-IP with domain mapping, multiple functional readouts\",\n      \"pmids\": [\"12370298\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Etk activation alone is sufficient to transcriptionally induce VEGF expression independent of HRE under normoxia; Etk utilizes both MEK/ERK and PI3K/Pak1 pathways to activate VEGF transcription; exogenous VEGF stimulates Etk tyrosine phosphorylation, forming a reciprocal Etk-VEGF autoregulatory loop.\",\n      \"method\": \"Northern/Western analysis, transient transfection with reporter genes, pharmacological pathway inhibition, antisense oligonucleotides\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal approaches in single lab, functional feedback loop demonstrated\",\n      \"pmids\": [\"12483534\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"TNF induces reciprocal activation between Etk and VEGFR2 (transactivation complex); Etk phosphorylation at Tyr566 directly mediates recruitment of the p85 subunit of PI3K; TNF-induced EC migration requires VEGFR2-Etk-PI3K-Akt signaling, and is abolished in Etk-deficient ECs.\",\n      \"method\": \"Co-immunoprecipitation, VEGFR2-specific inhibitors, Etk-deficient ECs (genetic deletion), Akt/PI3K inhibitors, EC migration assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO ECs, specific phospho-site mutation, multiple inhibitors, and direct binding demonstrated\",\n      \"pmids\": [\"14532277\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Bmx interacts with p130Cas at membrane ruffles, phosphorylates Cas on tyrosine residues, and promotes Cas-Crk complex formation; a Bmx mutant failing to interact with Cas fails to induce cell migration; dominant-negative Cas blocks Bmx-induced membrane ruffling and cell migration.\",\n      \"method\": \"Co-immunoprecipitation, colocalization (membrane ruffles), tyrosine phosphorylation assay, haptotactic migration assay, dominant-negative Cas expression\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — binding, phosphorylation, and functional rescue/block shown with multiple mutants and orthogonal approaches\",\n      \"pmids\": [\"12832404\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Etk/BMX physically associates with p53 through its SH3 domain and the proline-rich domain of p53; DNA damage-induced p53 inhibits Etk activity; Etk-p53 interaction (primarily cytoplasmic) leads to bidirectional inhibition of both proteins' activities; Etk inhibition of p53 prevents BAK interaction with mitochondria and confers doxorubicin resistance.\",\n      \"method\": \"SH3 domain array screening, co-immunoprecipitation, kinase activity assay, siRNA knockdown, reporter gene assay (p53 transcriptional activity)\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — SH3 array identification validated by Co-IP, bidirectional activity assays, siRNA functional rescue, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"15355990\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"EGF treatment induces Etk tyrosine phosphorylation; Etk overexpression potentiates EGF-induced apoptosis associated with STAT1 activation; kinase-domain deletion mutant EtkΔK blocks EGF-induced STAT1 activation and apoptosis; conditionally activated Etk alone (independent of EGF) stimulates STAT1 and induces apoptosis.\",\n      \"method\": \"Adenovirus-mediated overexpression, dominant-negative mutant, conditional activation system (ΔEtk:ER fusion), EMSA, reporter gene assay, flow cytometry\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional activation system plus DN mutant plus EMSA, single lab\",\n      \"pmids\": [\"14676838\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Bmx is identified as a component of PKC-ε signaling complexes in cardiac tissue (functional proteomic analysis); Bmx is activated by nitric oxide in the heart concomitant with the late phase of cardioprotection; NO donor-induced Bmx expression is blocked by PKC inhibitor chelerythrine.\",\n      \"method\": \"Functional proteomics of PKC-ε complexes, in vivo NO donor treatment in rabbits, PKC inhibitor chelerythrine\",\n      \"journal\": \"American journal of physiology. Heart and circulatory physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — proteomics-based complex identification plus pharmacological in vivo validation, single lab\",\n      \"pmids\": [\"15191890\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Pim-1 44 kDa isoform directly binds the SH3 domain of Etk/BMX via its N-terminal proline-rich motif, activating Etk kinase activity possibly by competing with p53; this interaction confers resistance to chemotherapeutic drugs in prostate cancer cells.\",\n      \"method\": \"Co-immunoprecipitation, GST-pulldown, kinase activity assay, drug resistance assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding shown by two independent methods (Co-IP and pulldown) with kinase activity readout, single lab\",\n      \"pmids\": [\"16186805\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Bmx is required for ischemia-mediated arteriogenesis and angiogenesis in vivo; Bmx-KO mice showed markedly reduced recovery after hindlimb ischemia while constitutively active Bmx transgenic mice showed enhanced recovery; bone marrow transplantation showed Bmx in bone marrow-derived cells plays a critical role in early ischemic tissue remodeling.\",\n      \"method\": \"Bmx genetic knockout and transgenic mice, hindlimb ischemia model, bone marrow transplantation, histological quantification of vessels\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO and constitutively active transgenic plus bone marrow transplantation, multiple functional and histological readouts\",\n      \"pmids\": [\"16932810\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Bmx is activated by tyrosine phosphorylation downstream of Src and PI3K in PTEN-deficient prostate cancer cells; Bmx associates with ErbB3 in LNCaP cells and heregulin-β1 enhances this interaction and Bmx activity; EGF stimulates a Bmx-EGFR interaction and rapidly increases Bmx kinase activity in a Src-dependent but PI3K-independent manner.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown, kinase activity assay, pharmacological inhibitors (Src, PI3K)\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus kinase assays plus siRNA knockdown, single lab\",\n      \"pmids\": [\"17823122\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Bmx regulates TLR4-induced IL-6 production in human macrophages by targeting the IL-6 3' UTR to increase mRNA stabilization via a p38 MAPK-independent pathway; Btk knockdown reduced TNF-α but not IL-6 production, demonstrating distinct roles.\",\n      \"method\": \"RNA interference, LPS stimulation, cytokine ELISA, mRNA stability assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNAi knockdown with mRNA stability assay differentiating Bmx from Btk, single lab\",\n      \"pmids\": [\"18025155\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"BMX is required for TNF-, IL-1β-, and TLR agonist-induced IL-8 secretion; BMX acts downstream of or at the TAK1-TAB complex level; BMX membrane localization (via its PH domain) is required for IL-8 promoter regulation; genetic deletion of BMX protects from K/BxN serum-transfer arthritis, but kinase-inactive BMX knock-in did not protect, revealing a kinase-independent in vivo function.\",\n      \"method\": \"Transient depletion (siRNA), epistasis analysis with TAK1-TAB, PH domain mutants, myristylation rescue, Bmx KO mice and kinase-inactive knock-in, passive K/BxN arthritis model\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple complementary genetic approaches (KO, kinase-dead knock-in) with in vivo disease model and mechanistic epistasis\",\n      \"pmids\": [\"21471444\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"BMX is associated with MyD88, FAK, and Mal in fibroblast-like synoviocytes (by co-immunoprecipitation); LPS and protein I/II induce phosphorylation of Etk/BMX and Mal via a FAK-dependent pathway; knockdown of Bmx or Mal inhibits IL-6 synthesis in response to LPS.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown, phosphorylation assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP showing complex plus siRNA functional validation, single lab\",\n      \"pmids\": [\"18292575\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"BMX is activated by RGD integrin stimulation in adult cardiomyocytes and co-distributes with STAT3 in detergent-insoluble fractions in pressure-overloaded myocardium; BMX and STAT3 form a complex and are co-phosphorylated in vivo without accompanying JAK2 activation; dominant-negative c-Src failed to block RGD-stimulated STAT3 or BMX changes.\",\n      \"method\": \"In vivo pressure overload model (feline RVPO), RGD peptide stimulation of cardiomyocytes, subcellular fractionation, co-immunoprecipitation, dominant-negative adenovirus\",\n      \"journal\": \"International journal of biological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo model with fractionation and Co-IP, dominant-negative epistasis, single lab\",\n      \"pmids\": [\"18612371\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Loss of Bmx prevents pressure overload-induced cardiac hypertrophy in mice; Bmx-KO mice were resistant to TAC-induced cardiac growth and preserved ejection fraction, establishing Bmx as a necessary mediator of pressure overload hypertrophic signaling.\",\n      \"method\": \"Bmx knockout mice, transverse aortic constriction (TAC) model, echocardiography, organ/cell-level hypertrophy quantification\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean genetic KO with defined in vivo functional phenotype (cardiac hypertrophy, ejection fraction), replicated across multiple readouts\",\n      \"pmids\": [\"18988895\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Clinical-stage irreversible EGFR inhibitors (e.g., CI-1033) potently and covalently inhibit Bmx by modifying Cys496 within the ATP-binding pocket.\",\n      \"method\": \"Biochemical kinase inhibition assay, sequence alignment, covalent modification analysis\",\n      \"journal\": \"Bioorganic & medicinal chemistry letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct biochemical demonstration of covalent modification at defined residue, single lab\",\n      \"pmids\": [\"18667312\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Etk/BMX directly interacts with the androgen receptor (AR) through its SH2 domain; this interaction prevents AR-Mdm2 association, stabilizing AR under androgen-depleted conditions; Etk overexpression increases AR tyrosine phosphorylation in prostate cancer cells.\",\n      \"method\": \"Co-immunoprecipitation, SH2 domain mapping, phosphorylation assay, androgen-depleted culture, siRNA knockdown\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct Co-IP with domain mapping and mechanistic consequence (AR stabilization), single lab\",\n      \"pmids\": [\"20570899\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Etk/BMX binds PAR1 via its PH domain to a seven-residue region (C378–S384) in the PAR1 C-tail; this binding enables subsequent Shc association; hPar1-7A mutant incapable of Etk binding is unable to drive invasion; Etk knockdown inhibits PAR1-induced cell migration.\",\n      \"method\": \"Antibody array, co-immunoprecipitation, domain-deletion and point mutants (Y/A PAR1), Matrigel invasion assay, siRNA knockdown\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — binding site mapped with mutants plus functional rescue/block, single lab\",\n      \"pmids\": [\"20559570\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"BMX activates STAT3 in glioblastoma stem cells (GSCs) to maintain self-renewal and tumorigenic potential; BMX knockdown inhibits STAT3 activation and GSC transcription factor expression; constitutively active STAT3 rescues the effects of BMX knockdown, placing BMX upstream of STAT3.\",\n      \"method\": \"shRNA knockdown, constitutively active STAT3 rescue, intracranial tumor growth assay, neurosphere formation\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis (CA-STAT3 rescue of BMX KD), in vivo tumor model, multiple readouts\",\n      \"pmids\": [\"21481791\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"BMX preferentially phosphorylates substrates with a priming phosphotyrosine at the -1 position (pYY motif); BMX phosphorylates FAK at Tyr577 subsequent to Src-mediated phosphorylation at Tyr576; BMX deficiency (RNAi or genetic KO in MEFs) markedly impairs FAK and insulin receptor kinase domain activation (pYY), as well as downstream Akt Thr308 phosphorylation.\",\n      \"method\": \"Positional scanning peptide library screening, in vitro kinase assay, RNAi, Bmx KO MEFs, Bmx KO mouse liver, phospho-specific antibodies\",\n      \"journal\": \"Science signaling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — substrate preference defined biochemically, validated in vitro and in multiple genetic KO models with orthogonal readouts\",\n      \"pmids\": [\"23716717\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"BMX covalently modifies Cys496 in a selective and irreversible manner; structure-based drug design yielded BMX-IN-1 (irreversible inhibitor) with nanomolar potency against Tel-BMX-transformed cells; kinome profiling confirms selectivity.\",\n      \"method\": \"Structure-based drug design, kinome profiling, covalent modification assay, cell proliferation assay\",\n      \"journal\": \"ACS chemical biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — structure-based design confirming Cys496 as covalent site, single lab\",\n      \"pmids\": [\"23594111\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"BMX associates with BAK in viable cells and phosphorylates a key tyrosine residue on BAK needed to maintain it in an inactive conformation; elevated BMX prevents BAK activation upon chemotherapy treatment; BMX silencing potentiates BAK activation and renders tumor cells hypersensitive to chemotherapeutic agents.\",\n      \"method\": \"Co-immunoprecipitation, kinase assay (BAK phosphorylation), siRNA knockdown, BAK activation assay, drug sensitivity assay\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct kinase-substrate relationship demonstrated (Co-IP + phosphorylation assay) with functional consequences validated by KD in multiple cancer lines\",\n      \"pmids\": [\"25649765\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Angiotensin II-induced cardiac hypertrophy is significantly reduced in Bmx KO and kinase-inactive Bmx knock-in mice; Ang II increases Bmx phosphorylation in endothelial cells; Bmx silencing inhibits downstream STAT3 signaling in endothelial cells; Bmx inactivation suppresses mTORC1 pathway activation by Ang II; human cardiac endothelial cells but not cardiomyocytes express abundant Bmx, indicating an endothelial-cardiomyocyte cross-talk mechanism.\",\n      \"method\": \"Bmx KO and kinase-inactive knock-in mice, Ang II infusion, genome-wide transcriptomics, Bmx siRNA in endothelial cells, mTORC1/STAT3 phosphorylation assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — two independent genetic models (KO and kinase-dead knock-in) plus transcriptomics and mechanistic signaling assays\",\n      \"pmids\": [\"26430242\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Phosphorylation of tyrosine 566 of the caspase-generated C-terminal BMX fragment relatively inhibits its proteasomal degradation via the N-end rule pathway; the cleaved BMX fragment has an N-terminal tryptophan that targets it for N-end rule degradation; pY566 is required for the pro-apoptotic function of the fragment.\",\n      \"method\": \"Metabolic stability assay, proteasome inhibitors, site-directed mutagenesis (Y566), caspase cleavage in PC3 cells, N-end rule reporter assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis and in-cell degradation assays establishing novel phospho-regulated proteolytic processing, single lab\",\n      \"pmids\": [\"27601470\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"BMX bypasses SOCS3-mediated inhibition of JAK2 to maintain STAT3 activation in GSCs; ibrutinib disrupts BMX-mediated STAT3 activation in GSCs but not in neural progenitor cells (which lack BMX and dampen JAK2/STAT3 via SOCS3); ibrutinib inhibits GBM growth and potentiates radiotherapy.\",\n      \"method\": \"Ibrutinib pharmacological inhibition, SOCS3 expression analysis, JAK2/STAT3 phosphorylation assays, GSC vs. NPC comparison, intracranial tumor models\",\n      \"journal\": \"Science translational medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — mechanistic epistasis (BMX-SOCS3-JAK2-STAT3) validated pharmacologically and in genetic models with in vivo tumor experiments\",\n      \"pmids\": [\"29848664\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"AR directly suppresses BMX gene expression by binding to the BMX gene; BMX expression rapidly increases following androgen deprivation; BMX contributes to CRPC by phosphorylating the pYY activation loop motif of multiple receptor tyrosine kinases; a BMX substrate-specific anti-pYpY antibody confirmed in vivo pYY substrate phosphorylation correlated with BMX expression.\",\n      \"method\": \"AR ChIP, androgen deprivation/castration models, cell line and xenograft CRPC models, BMX-IN-1 and ibrutinib treatment, phospho-specific antibody (anti-pYpY)\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP for direct AR regulation, xenograft in vivo validation, substrate antibody confirming in vivo substrate engagement\",\n      \"pmids\": [\"30012673\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"BMX localizes to the nucleus of endothelial cells via its SH3 domain; nuclear BMX (but not cytoplasm-targeted BMX) promotes Vegfr2 promoter activity by associating with and potentially phosphorylating transcription factor Sp1, increasing Sp1 binding to the Vegfr2 promoter; kinase-inactive BMX-K445R fails to promote Vegfr2 transcription.\",\n      \"method\": \"siRNA knockdown, luciferase reporter assay, chromatin immunoprecipitation (ChIP), nuclear/cytoplasmic fractionation, NLS- and NES-tagged BMX constructs, kinase-inactive mutant\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP for Sp1 binding, nuclear vs. cytoplasmic targeted constructs, kinase-dead mutant, multiple orthogonal methods in single study\",\n      \"pmids\": [\"31642192\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"BMX directly phosphorylates PAR1 and promotes its internalization and deactivation in endothelial cells; BMX loss increases thrombin-PAR1-mediated endothelial permeability 2- to 3-fold; PAR1 antagonist SCH79797 rescues BMX-KO-mediated vascular leakage in sepsis.\",\n      \"method\": \"BMX global KO mice, cecal ligation and puncture sepsis model, electric cell-substrate impedance sensing (ECIS), Miles assay, PAR1 phosphorylation and internalization assays, pharmacological PAR1 antagonist rescue\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO in vivo model plus direct PAR1 phosphorylation assay plus pharmacological rescue, multiple orthogonal methods\",\n      \"pmids\": [\"31910739\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"X-ray crystal structure of BMX covalently inhibited at Cys496 was determined; the structure reveals key interactions with Lys445 (critical for ATP catalysis) and a DFG-out-like inactive conformation.\",\n      \"method\": \"X-ray crystallography, covalent inhibitor design, kinase selectivity profiling, molecular dynamics simulations\",\n      \"journal\": \"RSC chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — first crystal structure of BMX covalent complex with direct structural validation of Cys496 binding and inactive conformation\",\n      \"pmids\": [\"34458764\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"BMX directly interacts with 3βHSD1 and phosphorylates it at Tyr344; this Y344 phosphorylation is required for 3βHSD1 cellular activity and generation of androgen/estrogen biosynthetic intermediates; in vivo blockade of 3βHSD1 Y344 phosphorylation inhibits CRPC.\",\n      \"method\": \"Co-immunoprecipitation of BMX and 3βHSD1, phospho-specific assay for pY344, in vitro kinase assay, patient tissue analysis, in vivo CRPC mouse model\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct kinase-substrate relationship (Co-IP + specific phospho-site assay + in vivo validation), replicated in patient tissues and mouse model\",\n      \"pmids\": [\"36647826\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Fas interacts with BMX in adipocytes via the Tyr189 site of Fas and the SH2 domain of BMX; this Fas/BMX complex mediates TNF-α-induced NF-κB and MAPK pathway activation and inflammatory cytokine release in adipocytes.\",\n      \"method\": \"Co-immunoprecipitation, site-directed mutagenesis (Fas Tyr189, BMX SH2), cytokine ELISA, NF-κB/MAPK activation assays\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus mutagenesis identifying interaction sites, single lab\",\n      \"pmids\": [\"34536556\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"In FLT3-ITD+ AML, hypoxia upregulates BMX in an HIF-dependent manner; BMX promotes AKT/mTOR and pSTAT5 signaling as a compensatory survival mechanism during FLT3 inhibition; pharmacological BMX inhibition or genetic KO reduces chemokine secretion and restores gilteritinib sensitivity.\",\n      \"method\": \"RNA-Seq of patient samples, murine FLT3-ITD model, in vitro hypoxia experiments, pharmacological BMX inhibition, CRISPR KO, signaling pathway assays (pSTAT5, pAKT)\",\n      \"journal\": \"Blood advances\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO and pharmacological inhibition with defined signaling readouts; HIF-dependent regulation shown in vitro and in vivo model\",\n      \"pmids\": [\"35797240\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"VEGF-A signals through BMX to induce VCAM-1 expression in human aortic endothelial cells; ibrutinib blocks BMX activation by VEGF-A and eliminates VEGF-A-stimulated VCAM-1 expression; ibrutinib inhibits endothelial VCAM-1 and platelet deposition in atherosclerosis-prone nonhuman primate carotid arteries in vivo.\",\n      \"method\": \"Ibrutinib and pharmacologically distinct BMX inhibitors in HAECs, flow cytometry, contrast-enhanced ultrasound molecular imaging in vivo (nonhuman primate)\",\n      \"journal\": \"Cellular and molecular bioengineering\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple inhibitors in vitro plus in vivo imaging in primate model, mechanistic link between VEGF-A, BMX, and VCAM-1 established\",\n      \"pmids\": [\"35611166\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"BMX is a Tec-family nonreceptor tyrosine kinase that is activated downstream of PI3K (via PH-domain-mediated membrane translocation), Src, and multiple cell-surface receptors (TNFR2, Tie-2, VEGFR1/2, EGFR/ErbB3, IL-3R, G-CSFR); once active, it phosphorylates a priming-pY-dependent pYY motif to amplify multiple downstream RTKs (FAK, insulin receptor), directly phosphorylates and activates STAT transcription factors, BAK (holding it inactive), PAR1 (promoting internalization), 3βHSD1 (enabling androgen biosynthesis), and the adaptor Cas (linking it to Crk-dependent actin remodeling and migration); nuclear-localized BMX additionally transactivates VEGFR2 transcription via Sp1; caspase cleavage generates a hyperactive C-terminal fragment whose stability is modulated by N-end rule-dependent proteasomal degradation controlled by Tyr566 phosphorylation; and an irreversible covalent bond with Cys496 within the DFG-out ATP pocket is the mechanistic basis of inhibition by ibrutinib and EGFR inhibitors.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"BMX (Etk) is a Tec-family nonreceptor tyrosine kinase, built from PH, SH3, SH2, and catalytic domains, that couples cell-surface receptor and PI3K signaling to cytoskeletal, survival, transcriptional, and angiogenic programs [#0, #2]. Its activation is gated by PI3K-dependent membrane translocation through its PH domain and by Src, downstream of a broad set of receptors including TNFR2, Tie-2/VEGFR1/2, EGFR/ErbB3, IL-3R, and G-CSFR [#2, #6, #10, #12, #21]. Once active, BMX phosphorylates substrates bearing a priming phosphotyrosine in a pYY activation-loop motif, amplifying FAK and the insulin receptor and feeding into Akt signaling [#31]. BMX directly activates STAT transcription factors independently of JAK to drive differentiation and tumor-cell self-renewal, and in glioblastoma stem cells it bypasses SOCS3-mediated JAK2 inhibition to sustain STAT3 [#1, #30, #36]. Through its SH2 and PH domains BMX engages effectors that control migration and survival: it phosphorylates p130Cas to promote Cas-Crk complexes and membrane ruffling [#15], phosphorylates BAK to hold it in an inactive conformation and confer chemoresistance [#33], binds and stabilizes the androgen receptor while phosphorylating 3\\u03b2HSD1 to enable androgen biosynthesis in castration-resistant prostate cancer [#28, #41], and phosphorylates PAR1 to drive its internalization and limit endothelial permeability [#39]. In the endothelium BMX is a node in angiogenesis and arteriogenesis, required for ischemic vascular recovery and acting nuclearly via its SH3 domain to transactivate the Vegfr2 promoter through Sp1 [#20, #38]. BMX is also a necessary mediator of pressure-overload and angiotensin II-induced cardiac hypertrophy, in part through kinase-independent functions revealed by kinase-dead knock-in mice [#23, #26, #34]. Caspase cleavage during apoptosis generates a hyperactive C-terminal fragment whose stability is set by Tyr566 phosphorylation acting on the N-end rule pathway [#11, #35]. A reactive Cys496 in the ATP pocket forms an irreversible covalent bond that is the structural basis for inhibition by ibrutinib and irreversible EGFR inhibitors, validated by crystallography of the inactive, DFG-out-like enzyme [#27, #32, #40].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Establishing that BMX is a bona fide enzyme: the cloned gene was shown to encode a multidomain (PH/SH3/SH2/kinase) nonreceptor tyrosine kinase with intrinsic catalytic activity.\",\n      \"evidence\": \"Transfection and immunoprecipitation of tyrosyl-phosphorylated BMX in COS and NIH3T3 cells\",\n      \"pmids\": [\"7970727\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No upstream activators or substrates identified\", \"Domain functions not yet dissected\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Defining the upstream gate: BMX was placed as a PI3K effector activated by PH-domain-mediated membrane recruitment, explaining how receptors funnel into BMX activation.\",\n      \"evidence\": \"Wortmannin inhibition, constitutively active p110 and dominant-negative p85 epistasis in IL-6-stimulated cells; later GFP membrane translocation imaging\",\n      \"pmids\": [\"9520419\", \"10962576\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Some receptor inputs (EGFR) later shown PI3K-independent\", \"Mechanism of membrane-induced conformational activation not resolved\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Linking BMX to gene expression: it directly activates STAT1/3/5 DNA binding and STAT-dependent transcription independent of JAK, identifying a transcriptional output arm.\",\n      \"evidence\": \"EMSA, reporter assays, and PKC isoform co-expression in mammalian and insect cells\",\n      \"pmids\": [\"9373245\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct STAT phosphorylation by BMX vs. indirect not fully separated here\", \"Physiological STAT targets context-dependent\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Placing BMX in the conserved Tec-kinase signaling logic: it reconstitutes PLC\\u03b32-dependent calcium and ERK signaling in Btk-null cells, defining a shared role as amplifier of receptor-proximal signal transduction.\",\n      \"evidence\": \"Genetic reconstitution in Btk-deficient DT40 B cells with calcium and ERK readouts\",\n      \"pmids\": [\"10224128\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Degree of functional redundancy with Btk/Tec in vivo unclear\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Connecting BMX to migration and cytoskeletal machinery: it binds Pak1 via its PH domain and associates with cell-surface receptors (TNFR2, Tie-2, VEGFR1) and caveolin-1, embedding it in endothelial signaling complexes.\",\n      \"evidence\": \"Co-IP, GST-pulldown, in vitro kinase assays, receptor activation assays, and Bmx knockout/knock-in reporter mice\",\n      \"pmids\": [\"11382770\", \"12370298\", \"11416142\", \"11751885\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Bmx KO mice initially showed no overt phenotype, implying redundancy\", \"Stoichiometry and assembly order of receptor complexes unresolved\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Defining migration substrates and a VEGF axis: BMX phosphorylates p130Cas to drive Cas-Crk complexes and ruffling, and engages in reciprocal transactivation with VEGFR2 with Tyr566 recruiting PI3K p85.\",\n      \"evidence\": \"Co-IP, colocalization at ruffles, phospho-site mutants, migration assays, and Etk-deficient endothelial cells\",\n      \"pmids\": [\"12832404\", \"14532277\", \"12483534\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether VEGF transactivation requires direct VEGFR2 phosphorylation by BMX not established\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Establishing dual life/death control: BMX interacts with p53 via its SH3 domain to bidirectionally inhibit p53 and confer drug resistance, while EGF-activated BMX can also drive STAT1-dependent apoptosis.\",\n      \"evidence\": \"SH3 domain array, Co-IP, kinase and reporter assays, conditional activation systems\",\n      \"pmids\": [\"15355990\", \"14676838\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Determinants of pro- vs. anti-apoptotic outcome context-dependent and unresolved\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Identifying allosteric activators: Pim-1 binds the BMX SH3 domain to activate it, possibly by competing with p53, linking BMX activity state to chemoresistance.\",\n      \"evidence\": \"Co-IP, GST-pulldown, kinase and drug-resistance assays in prostate cancer cells\",\n      \"pmids\": [\"16186805\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Competition model with p53 inferred, not directly demonstrated\", \"Single lab\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Demonstrating in vivo vascular and inflammatory requirement: Bmx is required for ischemic arteriogenesis/angiogenesis and for receptor-induced inflammatory cytokine output, including a kinase-independent arthritis function.\",\n      \"evidence\": \"Bmx KO and constitutively active transgenic mice, hindlimb ischemia, bone marrow transplant; siRNA and TAK1-TAB epistasis with kinase-dead knock-in in K/BxN arthritis\",\n      \"pmids\": [\"16932810\", \"21471444\", \"18025155\", \"18292575\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanistic basis of kinase-independent in vivo function not defined\", \"Cell-type-specific contributions only partly resolved\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Establishing BMX as a cardiac hypertrophy mediator: loss of Bmx protects against pressure-overload hypertrophy, and BMX participates in PKC-\\u03b5/STAT3 cardioprotective complexes.\",\n      \"evidence\": \"Bmx KO mice with TAC and echocardiography; functional proteomics of PKC-\\u03b5 complexes and RGD/STAT3 fractionation studies\",\n      \"pmids\": [\"18988895\", \"15191890\", \"18612371\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cardiomyocyte vs. endothelial source of relevant BMX initially ambiguous\", \"Downstream effectors in heart incompletely mapped\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Mapping prostate-cancer effectors: BMX stabilizes AR via SH2-domain binding (blocking AR-Mdm2) and binds PAR1 via its PH domain to drive invasion.\",\n      \"evidence\": \"Co-IP, SH2/PH domain mapping, PAR1 point mutants, invasion and migration assays in androgen-depleted conditions\",\n      \"pmids\": [\"20570899\", \"20559570\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct AR phosphorylation by BMX vs. binding-only stabilization not fully separated\", \"Single lab for each interaction\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Establishing a tumor stem-cell role: BMX maintains glioblastoma stem cell self-renewal by acting upstream of STAT3, with constitutively active STAT3 rescuing BMX loss.\",\n      \"evidence\": \"shRNA knockdown, CA-STAT3 rescue, neurosphere and intracranial tumor assays\",\n      \"pmids\": [\"21481791\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor input activating BMX in GSCs not defined here\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Defining substrate specificity rules: BMX recognizes a priming pYY motif and phosphorylates the FAK and insulin-receptor activation loops to amplify RTK signaling into Akt.\",\n      \"evidence\": \"Positional scanning peptide library, in vitro kinase assays, RNAi, Bmx KO MEFs and liver with phospho-specific antibodies\",\n      \"pmids\": [\"23716717\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full physiological pYY substrate repertoire not enumerated\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Mechanizing chemoresistance: BMX phosphorylates BAK to hold it inactive, so BMX silencing potentiates apoptosis; in parallel BMX is required for angiotensin II-driven cardiac hypertrophy through endothelial STAT3/mTORC1 signaling.\",\n      \"evidence\": \"Co-IP and BAK phosphorylation/activation assays with drug sensitivity; Bmx KO and kinase-dead knock-in mice with Ang II infusion and transcriptomics\",\n      \"pmids\": [\"25649765\", \"26430242\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"BAK tyrosine site identity and structural consequence not fully defined\", \"Endothelial-to-cardiomyocyte cross-talk signal not molecularly identified\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Resolving regulation of the apoptotic fragment: caspase cleavage yields a hyperactive C-terminal BMX with an N-terminal tryptophan, and Tyr566 phosphorylation stabilizes it against N-end rule degradation to enable its pro-apoptotic function.\",\n      \"evidence\": \"Metabolic stability assays, proteasome inhibitors, Y566 mutagenesis, N-end rule reporters in PC3 cells\",\n      \"pmids\": [\"27601470\", \"11278797\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Upstream kinase for Tyr566 of the fragment not identified\", \"Physiological contexts of fragment generation limited\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Establishing a targeted therapeutic axis: AR directly represses BMX, so androgen deprivation derepresses BMX, which phosphorylates pYY motifs of multiple RTKs to drive castration-resistant prostate cancer; BMX also bypasses SOCS3 to sustain STAT3 in glioblastoma, sensitizing both to ibrutinib.\",\n      \"evidence\": \"AR ChIP, castration/xenograft models, anti-pYpY substrate antibody, BMX-IN-1 and ibrutinib; SOCS3/JAK2/STAT3 assays and intracranial GBM models\",\n      \"pmids\": [\"30012673\", \"29848664\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full set of RTKs amplified in CRPC not exhaustively defined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Discovering a nuclear transcriptional role: BMX enters the endothelial nucleus via its SH3 domain and transactivates the Vegfr2 promoter by acting on Sp1 in a kinase-dependent manner.\",\n      \"evidence\": \"NLS/NES-tagged and kinase-dead constructs, fractionation, luciferase reporters, and Sp1 ChIP\",\n      \"pmids\": [\"31642192\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct Sp1 phosphorylation by nuclear BMX shown only as potential\", \"Nuclear import mechanism beyond SH3 dependence unresolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Defining endothelial barrier and structural mechanism: BMX directly phosphorylates PAR1 to drive internalization and restrain vascular leakage, and the covalent Cys496 inhibitor complex was crystallized in a DFG-out-like inactive state.\",\n      \"evidence\": \"Bmx KO mice in CLP sepsis with ECIS, Miles assay, PAR1 phosphorylation and PAR1-antagonist rescue; X-ray crystallography with molecular dynamics\",\n      \"pmids\": [\"31910739\", \"34458764\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Active-state BMX structure not determined\", \"Reconciliation of PAR1 pro-invasive vs. barrier-protective roles across tissues incomplete\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Adding a metabolic effector and disease links: BMX phosphorylates 3\\u03b2HSD1 at Tyr344 to enable androgen biosynthesis in CRPC, and acts as a hypoxia/HIF-induced compensatory survival kinase in FLT3-ITD AML and a VEGF-A-driven mediator of endothelial VCAM-1 in atherosclerosis.\",\n      \"evidence\": \"Co-IP, pY344-specific and in vitro kinase assays, patient tissue and CRPC mouse models; CRISPR KO and inhibitors in AML; multiple BMX inhibitors and in vivo primate imaging in vascular models\",\n      \"pmids\": [\"36647826\", \"35797240\", \"35611166\", \"34536556\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct receptor input upstream of BMX in AML hypoxia not fully defined\", \"Adipocyte Fas/BMX inflammatory axis from single Medium-confidence study\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How BMX integrates its many receptor inputs, intramolecular regulation, and the choice between pro-survival and pro-apoptotic outputs in a given cell remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No active-state structure to explain receptor-specific activation modes\", \"Logic determining BAK/STAT-driven survival vs. STAT1/fragment-driven apoptosis undefined\", \"In vivo substrate repertoire incompletely mapped\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 15, 31, 33, 39, 41]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 1, 31]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [1, 30, 38]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [2, 6]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [16, 28, 33]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [2, 6, 12, 23]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [38]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [16, 25]},\n      {\"term_id\": \"GO:0005856\", \"supporting_discovery_ids\": [15]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [2, 14, 31, 36]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [22, 23, 24, 42]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [11, 16, 17, 33, 35]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [30, 36, 37, 41, 43]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [1, 30, 38]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"STAT3\", \"FAK\", \"BCAR1\", \"BAK1\", \"TP53\", \"AR\", \"F2R\", \"VEGFR2\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":9,"faith_total":9,"faith_pct":100.0}}